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ABSTRACT 
ii 
Human serum albumin, a multidomain and major soluble 
protein constituent of the circulatory system have many 
physiological functions. The albumin contributes 
significantly to colloid osmotic blood pressure and aid in 
transport,distribution and metabolism of many endogenous and 
exogenous ligands. These ligands represent a spectrum of 
chemically diverse molecules, including fatty acids, 
bilirubin, amino acids, steroids, inorganic ions and 
numerous pharmaceuticals. The interaction of bilirubin to 
HSA is of pathological relevance since free bilirubin 
(cytoxic and neurotoxic) is rendered nontoxic upon 
complexation with albumin. Moreover the interaction of broad 
spectrum of drugs to HSA and their bilirubin displacing 
behaviour marks it as of prime importance. Though 
extensively studied, the bilirubin and drugs binding 
sites at albumin molecule has not to be discerned 
completely. In the present work a systematic study of these 
interactions and drug induced bilirubin displacement 
phenomenon has been under taken to understand the molecular 
basis of these interaction and displacement processes. 
A fluorescence quench titration method was used to 
study the interaction of various drugs, namely, 
indomethacin (an anti-inflamatory drug), salicylic acid (an 
analgesic agent), and chlorpromazine (an antipsychotic drug) 
Ill 
to HSA under varying experimental conditions i.6. 
temperature, ionic strength and pH. It was observed that the 
emission of HSA ( 340 nm) shows quenching upon the addition 
of micromolar concentrations of drug, at excitation 
wavelength of 284 nm in emission region of 300-400 nm. The 
method was found to be as highly precise and successful for 
studying the drug albumin interaction. The quantification of 
drug binding data (as association constants) reflected well 
with earlier reports. The varying temperature data (as 
thermodynamic parameters), ionic strength and pH trends 
showed that idomethacin-HSA interactions are mainly based on 
hydrophillic (electrostatic) interaction with a possible 
role of hydrophobic interaction, as secondarily, while the 
opposite trend was obtained with salicylic - HSA 
interaction, as primarily due to hydrophobic followed by 
electrostatic interactions. In case of chlorpromazine-HSA 
interactions the solely involvement of hydrophobic 
interactions was observed. 
In order to investigate the possible role of lysine 
residues in drug/bilirubin interaction to HSA various 
carbamylated derivatives of HSA having 98%, 77%, 55% and 
23% modifications were prepared. Additionally a carbamylated 
preparation with (21%) modification at buried lysine 
residues was achieved by using double modification 
technique, as earlier standarized in our laboratory. All 
these carbamylated derivatives were found to be homogenous 
with respect to size and charge as judged by gel 
chromatography and polyacrylamide gel electrophoresis. The 
(21%) carbamylated derivative showed no or insignificant 
conformational changes, thus proved its utility in ligand 
binding as compared to significant changes in conformation 
upon carbamylation with other derivatives. 
All the modified preparations of HSA were used to 
study the bilirubin/drug interactions by fluorescence quench 
method. The indomethacin interactions with modified HSA's 
showed as a clear role of buried lysine residues in this 
interaction, since a 76 fold decrease in association 
constant, Ka was obtained with (21%) carbamylated derivative 
as compared to only 9 fold with maximally modified 
derivative i.e. 98% of HSA . The reverse trend was obtained 
with salicylic acid as only a 3 fold decrase in Ka was 
observed with (21%) modification as to that of 51 fold 
decrease with 98% modified derivative. This showed that 
exposed lysine residues are critical for salicylic acid-
HSA interaction chlorpromazine, while an insignificant 
change in Ka was obtained either with exposed or with 
buried lysine modified HSA derivatives. Thus, it appears as 
that none of exposed/buried lysine residue are important 
in chlorpromazine-HSA interaction. The interaction of 
bilirubin with modified derivatives of HSA showed a marginal 
decrease (53 fold in Ka) with (21%) carbamylated preparation 
and about 76 fold decrease with 98% modified derivative. It 
showed that the nature of lysine residue(s) is of probably 
buried/partially buried to bilirubin on albvunin molecule. 
Drug induced bilirubin displacement from bilirubin 
albumin complex was studied by a novel approach of 
fluorescence enchancement. It was observed that bilirubin 
upon complexation with albumin gives an emission maxima at 
528 nm, at excitation wavelength of 487 nm. The peak showed 
an enhancement pattern upon increasing micromolar 
concentration of bilirubin over albumin. However, addition 
of drug showed an decrease in fluorscence intensity at 528, 
probably due to release to bilirubin from its complex with 
albumin. Therefore, this * fluorescence enhancement' 
methodology was under taken to study the drug induced 
bilirubin displacement from human serum albmuin. A modified 
version of quenching was employed to compute the 
association constants in the presence and absence of drug 
from enhancement data. It was found that at higher drug 
concentrations ( 100 jM) indomethacin serves as a potent 
bilirubin displaces (with a 9 fold decrease in ka) followed 
by chlorpromazine and salicylic acid, with a 7 and 5 fold 
decrease in association constant respectively. The 
transformation of displacement data was made into double 
receiprocal plots, for better understanding of the nature 
VI 
of drug induced bilirubin displacement from albumin. The 
results showed the nature of indomethacin and salicylic acid 
were as of competitive and non competetive bilirubin 
displacing agents repsectively, while a mixed response of 
competetive and non competetive, was obtained for 
chlorpromazine induced bilirubin displacement from albumin. 
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Human serum albumin, a multidomain and major soluble 
protein constituent of the circulatory system have many 
physiological functions. The albumin contributes 
significantly to colloid osmotic blood pressure and aid in 
transport,distribution and metabolism of many endogenous and 
exogenous ligands. These ligands represent a spectrum of 
chemically diverse molecules, including fatty acids, 
bilirubin, amino acids, steroids, inorganic ions and 
numerous pharmaceuticals. The interaction of bilirubin to 
HSA is of pathological relevance since free bilirubin 
(cytoxic and neurotoxic) is rendered nontoxic upon 
complexation with albumin. Moreover the interaction of broad 
spectrum of drugs to HSA and their bilirubin displacing 
behaviour marks it as of prime importance. Though 
extensively studied, the bilirubin and drugs binding 
sites at albumin molecule has not to be discerned 
completely. In the present work a systematic study of these 
interactions and drug induced bilirubin displacement 
phenomenon has been under taken to understand the molecular 
basis of these interaction and displacement processes. 
A fluorescence quench titration method was used to 
study the interaction of various drugs, namely, 
indomethacin (an anti-inflamatory drug), salicylic acid (an 
analgesic agent), and chlorpromazine (an antipsychotic drug) 
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to HSA under varying experimental conditions i.e. 
temperature, ionic strength and pH. It was observed that the 
emission of HSA ( 340 nm) shows quenching upon the addition 
of micromolar concentrations of drug, at excitation 
wavelength of 284 nm in emission region of 300-400 nm. The 
method was found to be as highly precise and successful for 
studying the drug albumin interaction. The quantification of 
drug binding data (as association constants) reflected well 
with earlier reports. The varying temperature data (as 
thermodynamic parameters), ionic strength and pH trends 
showed that idomethacin-HSA interactions are mainly based on 
hydrophillic (electrostatic) interaction with a possible 
role of hydrophobic interaction, as secondarily, while the 
opposite trend was obtained with salicylic - HSA 
interaction, as primarily due to hydrophobic followed by 
electrostatic interactions. In case of chlorpromazine-HSA 
interactions the solely involvement of hydrophobic 
interactions was observed. 
In order to investigate the possible role of lysine 
residues in drug/bilirubin interaction to HSA various 
carbamylated derivatives of HSA having 98%, 77%, 55% and 
23% modifications were prepared. Additionally a carbamylated 
preparation with (21%) modification at buried lysine 
residues was achieved by using double modification 
technique, as earlier standarized in our laboratory. All 
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these carbamylated derivatives were found to be homogenous 
with respect to size and charge as judged by gel 
chromatography and polyacrylamide gel electrophoresis. The 
(21%) carbamylated derivative showed no or insignificant 
conformational changes, thus proved its utility in ligand 
binding as compared to significant changes in conformation 
upon carbamylation with other derivatives. 
All the modified preparations of HSA were used to 
study the bilirubin/drug interactions by fluorescence quench 
method. The indomethacin interactions with modified HSA's 
showed as a clear role of buried lysine residues in this 
interaction, since a 76 fold decrease in association 
constant, Ka was obtained with (21%) carbamylated derivative 
as compared to only 9 fold with maximally modified 
derivative i.e. 98% of HSA . The reverse trend was obtained 
with salicylic acid as only a 3 fold decrase in Ka was 
observed with (21%) modification as to that of 51 fold 
decrease with 98% modified derivative. This showed that 
exposed lysine residues are critical for salicylic acid-
HSA interaction chlorpromazine, while an insignificant 
change in Ka was obtained either with exposed or with 
buried lysine modified HSA derivatives. Thus, it appears as 
that none of exposed/buried lysine residue are important 
in chlorpromazine-HSA interaction. The interaction of 
bilirubin with modified derivatives of HSA showed a marginal 
decrease (53 fold in Ka) with (21%) carbamylated preparation 
and about 76 fold decrease with 98% modified derivative. It 
showed that the nature of lysine residue(s) is of probably 
buried/partially buried to bilirubin on albumin molecule. 
Drug induced bilirubin displacement from bilirubin 
albumin complex was studied by a novel approach of 
fluorescence enchancement. It was observed that bilirubin 
upon complexation with albumin gives an emission maxima at 
528 nm, at excitation wavelength of 487 nm. The peak showed 
an enhancement pattern upon increasing micromolar 
concentration of bilirubin over albumin. However, addition 
of drug showed an decrease in fluorscence intensity at 528, 
probably due to release to bilirubin from its complex with 
albumin. Therefore, this * fluorescence enhancement' 
methodology was under taken to study the drug induced 
bilirubin displacement from human serum albmuin. A modified 
version of quenching was employed to compute the 
association constants in the presence and absence of drug 
from enhancement data. It was found that at higher drug 
concentrations ( 100 uM) indomethacin serves as a potent 
bilirubin displaces (with a 9 fold decrease in ka) followed 
by chlorpromazine and salicylic acid, with a 7 and 5 fold 
decrease in association constant respectively. The 
transformation of displacement data was made into double 
receiprocal plots, for better understanding of the nature 
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of drug induced bilirubin displacement from albumin. The 
results showed the nature of indomethacin and salicylic acid 
were as of competetive and non competetive bilirubin 
displacing agents repsectively, while a mixed response of 
competetive and non competetive, was obtained for 
chlorpromazine induced bilirubin displacement from albumin. 
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INTRODUCTION 
General characteristics: 
Serum albumins belong to a multigene family of 
proteins that includes <K/ -fetoprotein (AFP) and human 
groups specific component (Gc) or vitamin D binding 
protien. As the major soluble protein in circulatory system 
and with typical blood concentration of 50 mg/ml, albumin 
contributes 80% to osmotic pressure (Peters, 1985). In 
addition, it has now been determined that it is chiefly 
responsible for the maintenance of blood pH (Figge et al., 
1991). 
Besides high aqueous solubility, net negative charge at 
physiological pH, lack of carbohydrate moiety and stability, 
the most outstanding property of albumin is its ability to 
bind reversibly an incredible variety of ligands such as 
inorganic ions, organic dyes and broad spectrum of drugs 
etc. (Peters, 1985; Carter and Ho, 1994). As a principal 
carrier of fatty acids that are insoluble in circulatory 
plasma, it performs many other functions, as well, such as 
sequestering oxygen free radicals and inactivating various 
lipophillic metabolities like bilirubin ( Halliwell, 1988; 
Emerson, 1989). 
The role of albumin as a key carrier or reservoir of 
nitric oxide, which has been implicated in number of 
physiological processes including neurotransmission serves 
to illustrate further the continuing recognition of the 
utility of albumin (Stambler et al., 1992). Thus, without 
question, albumin is the most multifunctional transport 
protein known to date. 
A lot of work has been done in past few decades 
which has been reviewed by some prominent researchers like: 
Foster (1960), Kragh Hansen (1981), Fehske et al., (1981), 
Finlayson (1980), Alexander et al., (1982), Peters (1985, 
1992), Rothschild et al., (1988) and Carter and Ho (1994). 
Recently, the three dimensional structure of human 
serum albumin has been determined crystallographically (He 
and Carter, 1992) to a resolution of 2.8A°. Several crystals 
of human (He and Carter, 1992) and bovine albumin (Carter 
et al., 1994) have been grown in microgravity environment 
(Miller et al,. 1992). Indeed, the group of American 
Scientist, Daniel C. Carter has made a hallmark in the 
atomic structure and chemistry of serum albumins. 
Biosynthesis and •olecular genetics: 
Serum albumin is synthesized in liver in the form of 
'preproalbumin', containing a leader sequence (signal 
peptide) of 18 amino acid residues (Mac Gillivray et al., 
1979; Schafritz, 1979; Kreil, 1981). The signal peptide is 
cleaved to give rise to 'prealbumin' which caries an amino 
terminal hexapeptiede (Arg-Gly-Val-Phe-Arg-Arg), (Judah and 
Quinn, 1976; Strauss et al., 1977; Compere et al., 1981). 
The prealbumin is converted to albumin by the removal of 
extension peptide. The liberated propeptide is broken down 
in liver cells without any effect on albumin synthesis 
(Peters and Davidson, 1986). Albumin mRNA has been 
isolated from the liver cytoplasm (Keller and Taylor, 
1979) and complementary DNA (cDNA) molecule have been 
cloned. Thus, with cDNA as hybridization tool the genes for 
human (Hawkins and Dugaiczyk, 1982), rat (Sargent et al., 
1981), frog (May et al., 1982), equine (Ho et al., 1993) and 
other serum albumins have been isolated. A single copy of 
albumin gene has been found in human and rat genome. The 
human gene has been located at the proximal end of long arm 
of hiaman chromosome 4 (Minghetti et al., 1986) in the same 
region where the genes for AFP (Harper and Dugaiczyk, 1983) 
and Gc component are present (Mikkelsen et al., 1977). The 
Gc component is an o^ 2~9lot)ulin which is now realized to be 
the vitamin D binding protein of plasma (Peters, 1985), a 
member of multigene famity with AFP and serum albumins. 
The albumin (human) gene has 16,961 base pairs 
(Minghetii et al., 1986), approximately ten times the length 
of coding segment which contains 1830 base pairs. There 
are 14 introns and 15 exons in albumin gene. The exons are 
designated by the letters ZABCDEFGHIJKLMN. Their lengths 
foriti a pattern of triplet homology corresponding to three 
domains of albumin (Peters, 1985). The leader exon z 
contains 5'-untranslated portion of mRNA including the 
initiation and capping sites. It also encodes the 18 residue 
signal peptide and 6 residue propeptide and the first 2 1/3 
residues of albumin chain. Exons ABCD, EFGH, and IJKL encode 
for domains I, II and III in sequence. Exon M encodes for 
residues 571-585 (Minghetti et al., 1986) in the C terminal 
tail and contains terminal codon. Last one (N) is not 
translated but contains the site for polyadenylation and 3' 
terminus of the gene. The only noted discrepancy among 
albumins is of 7 domain lamprey serum albumin (Gray and 
Doolittle, 1992) is posibly due to an incomplete gene 
fusion. 
PhysicocheBical properties; 
Some of the physicochemical properties of HSA are 
summaized in Table I. Human serum albumin, a protein of 
M^ 67K exists as a single polypeptide chain (Thompson, 
1958; Hunter and Mc Duffie, 1959). Based, largely on 
hydrodynamic (Huges, 1954, Squire et al., 1968, Wright and 
Thompson, 1975), low angle scattering and electron 
microscopic studies (Bloomfield, 1966; Moser et al., 1966; 
Chatterjee 1965), the early conception of serum albumin 
TABLE - I 
PHYSICOCHEMICAL PROPERTIES OF HDMAN SERDM ALBUMIN 
PROPERTY VALUE REFERENCE 
Molecular weight 
(a) From composition 
(b) From physical data 
Sedimentation constant 
S°so,wxlO-'^ -' 
Diffusion coefficient 
D°20, Wxio" _ 
Partial specific volume, Vj 
Intrinsic viscosity, r^  
Specific absorbance 
(ig litre"-^ )at 279nm 
Isoelectric point 
Isoionic point 
Helical content 
6-turn 
TWet Charge (at pH 7.0) 
Hydrodynamic radius 
(rotational), A° 
Overall dimension , A 
Molecular dimension: 
Eguilater triangle (Shape) 
Side, A° 
depth. A° 
Molecular volume, fp^ 
Molecular surface area, A°^ 
Radius of gyration, fP 
66.439 
69.000 Charswood (1961) 
4.5 S Oncley et al.(1947) 
6.0 
0.733 
0.042(N) 
0.16 (F) 
0.531 
4.7 
5.3 
65% 
10% 
•15 
26.4 
140X40A 
80 
30 
88248.9 
28202.1 
26.7 
Oncley et al.(1947) 
Charlswood (1961) 
Chaiswood (1961) 
Edward et al.(1961) 
Carter and Ho (1994) 
Carter and Ho (1994) 
He and Carter(1992) 
Carter and Ho (1994) 
Peters (1985) 
Cannistraro and 
Sacchetti (1986) 
Feng et al.(1988) ^ 
Carter and Ho(1994) 
* Obtained from the atomic coordinates of HSA (He and Carter, 
1992). 
began to converge on the shape of an oblate ellipsoid 
having dimension or axis of -^ 140x40A°, supported by 
Bendedouch and chen, 1983 and Feng et al., 1988. 
Attempts have been made to elucidate the structural 
aspects of albumin by x-ray crystallography and resulted 
with a poor success (McClure and Craven, 1974; McPherson, 
1976, and Rao et al., 1976). Crystals of HSAs (Wild type and 
of recombinant form, expressed in yeast) have been obtained 
successfully (He and Carter, 1992) from solutions of 
defatted protein in polyethylene glycol at neutral pH 
(Carter et al., 1989). Earlier, the low resolution 
t 
crystallographic analysis of HSA (due to its special packing 
arrangement in crystal) has shown that the cigar-shaped 
model was plausible (Carter et al., 1989, Carter and He, 
1990). Low resolution darkfield micrograph of AFP, the fetal 
counterpart of albumin revealed its shape as U type (Luft 
and Lorscheider, 1983). Meanwhile, on the basis of 
fluorescence energy transfer, Hagag and collegues (1983) 
referred that albumin must be folded more in accordance 
with a U shape model. Finally ^H NMR and crystallographic 
studies at a resolution of 2.8A° ( He and Carter, 1992) 
have concluded that an oblate ellipsoid structure of HSA 
was unlikely rather, it was proposed that HSA was folded 
into heart shape structure quiet similar to AFP (Bos et 
al., 1989). Various parameters of this heart shape HSA 
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molecule are given in Table I. Various spectroscopic 
(Sjoholm and Ljungstedt, 1973; Reed et al., 1975; Foster, 
1977) and predictive methods ( McLacham and Walker, 1977) 
showed that the major secondary structure component of 
albumin are, <</-helical structures (55-75%) and A Sheets 
(18%). Later on, it was found that ^  67% helical contents 
and --23% extended chain structure is present in albumin 
(Pearson, 1990). Further, this 23% extended chain structure 
has been identified as 5 strands and remaining ^ 10% as 
turn in HSA molecule (Carter and Ho, 1994). 
Heterogeneity and conformational States: 
Albumin is synthesized as a single polypeptide chain 
but often showns heterogeneity during its life span . The 
genetic variation of albumin such as bisalbuminemia, 
polymorphism (Tarnoky, 1980), analbuminemia (Dammacco et 
al., 1980; Russi and Weigand, 1983) are very rare. To date, 
the positions of 43 single site point mutations in HSA have 
been determined (Carter and Ho, 1994). Infact there are 
several other causes of heterogeneity which may arise 
because of protein-protein association, ligand binding 
(Guillani et al, 1981, Moehing et al., 1983, Peters, 1985, 
Honore, 1987) and conformational isomerization. 
HSA is a labile molecule and changes its conformation 
with change in the pH of medium. Several isomeric forms of 
albumin, induced reversibly as a function of pH has been 
well documented (Foster, 1960, 1977). Between pH 5.0 to 7.0, 
albumin molecule exists as "N" (for normal) state. Anotehr 
state "F" (for fast moving) forms abruptly at pH values 
less than 4.0. This well known N ^ —r F transition is 
characterized by an increase in electrophoretic mobility 
(Foster, 1960), increase in tyrosyl exposure (Herskovits and 
Laskowski, 1962), increase in helical content (Hilak et al., 
1974) and dramatic increase in intrinsic viscosity (Tanford 
et al., 1967). Feng et al. (1988) have found that "F" form 
binds to the surface of highly oriented pyrolytic graphite 
as revealed by scanning tunneling microscopy. Thus, N-'-^ F 
transition seems to be of physiological significance 
(Wilting et al., 1982, Carter and Ho, 1994). When pH is 
lowered upto 3.0, albumin undergoes another form "E" (for 
expanded form) with approximate dimension of 21 x250 A° 
(Harrington et al., 1956). It seems reasonable to expect 
that "E" form corresponds to the sequential subdomain-
subdomain dissociation concomitant with loss of interdomain 
helices (Carter and Ho, 1994). 
Increase in pH from 7.0 to 9.0 transforms albumin into 
another conformationally distinct species referred to as "B" 
(for basic) state. This state is characterized by a small 
decrease in helical content (Zurawski and Foster, 1974; Era 
et al., 1990) and less anodic mobility in electrophoresis. 
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structurally the "B" change occurs more slowly than "F" 
transition and discrete steps are associated with it (Hart 
et al., 1986). Increase in affinity for selected ligands 
have been reported during this N^ -—rB transition (Zurawski 
and Foster, 1974; Wilting et al., 1980a, 1980b; vander 
Giesen and Wilting, 1982; Droge et al., 1982; Vorum, 1987, 
Era et al., 1990). Treatment of albumin solution at pH 9.0 
for 3-4 days converts it to another isomeric form termed as 
"A" (for aged) form. It has been shwon that this inyolves 
disulfide interchange reaction involving the lone sulfydryl 
group of albumin (Stroupe and Foster, 1973). 
Structural Organization: 
Human serum albumin is a single polypeptide chain of 
585 amino acid residues. It's amino acid sequence contains a 
total 17 disulfide bridges, one free thiol (Cys-34) and a 
single Tryptophan (Trp 214). The number of acidic amino 
acids (Asp and Glu) is higher as compared to basic amino 
acids (His, Lys and Arg) giving an acidic character to 
albumin molecule. Albumin molecule is devoid of any carbohy-
drate moieties. However, in vitro treatment of albumin with 
glucose (also in untreated diabetic patients) may produce 
glycosylated albumin (Shaklai et al., 1984). 
The primary structure of human (Dugaiczyk et al. , 
1982), bovine (Brown and Shockley, 1982), rat (Sargent et 
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al., 1983), sheep ( Brown et al., 1989), frog{Moskaitis et 
al., 1989), selinon (Minghetti, et al., 1985), pig 
(Weinstock and Baldwin, 1988), equine (Ho et al., 1993) and 
sea lamprey (Gray and Doolittle, 1992) serum albumins have 
been worked out. A total of 61% amino acid sequences are 
conserve among human, bovine and rat serum albumins (Carter 
and Ho, 1994). The primary structure of human serum albumin 
is shown in Fig.l. 
The critical feature of albumin structure is its 
organization into three homologous structural domains, I, II 
and III. (Brown, 1977; He and Carter, 1992). Interestingly, 
the only known exception of three domain model is of 
Lamprey albumin, which has seven domain (Gray and 
Doolittle, 1992). These domain corresponds to residues 1-
190, 191-382 and 383-585 in HSA. 
Earlier, Brown (1977) showed that each domain was a 
product of 3 subdomains (2 large and one small). This 
organization of albumin molecule in 6 large and 3 small 
subdomains, proposed by Brown (1977) came to end by the 
atomic structure of HSA, determined crystallographically (He 
and Carter, 1992). The three dimensional structure of HSA, 
determined crystallographically to a resolution of 2.8 A" , 
suggests that each domain is a product of two subdomains 
that possess common structural motifs (He and Carter, 
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5 
6 
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H 
Fig. 1. Amino acid sequence of Human serum albumin (Ledden 
& Feldhoff ., 1983).Position of disulfide are shown 
by (D ) Number 1-9 indicate the nine double loops 
of protein molecule. 
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1992). Thus, these six subdomain (lA, IB etc.) assemble to 
form a heart shaped molecule. The topology of an ideal 
domain is shown in Fig.2. There are 10 principal helices 
in each domain (hl-hlO). Subdomain A and B share a common 
motif that includes hl,h2,h3, h4,h5 and h6 for subdomain A 
and h7, h8, h9 and hlO for sudomain B. The principal 
portion of each subdomian is formed by one of the 6 larger 
disulfide loops (Fig. 1) often referred as earlier (Peters, 
1985) as 1,3,4,6,7 and 9. Three of these loops, 1,4 & 7 are 
each supplemented by an additional, but smaller disulfide 
double loop (2,5 and 8) respectively). Consequently the 
combinations of loops 1 and 2, 4 and 5, 7 and 8 represent 
three A subdomains (lA, IIA, IIIA) and loops 3.6 and 9, the 
B subdomains (IB, IIB, IIB). Two largest helices in the 
structure occur at interdomain connections (IB- IIA and IIB-
IIIA) and represent the merged C terminal and N termianl 
helices of both domains. Thus, the total number of helices 
is 28 rather than 30 (He and carter, 1992). 
The shape of albumin is markedly asymmetric and has 
been aproximated to a solid equilateral triangle with 
sides of 80A° and average depth of 30 A° (See table I). 
In addition to this the albumin molecule is not uniformly 
charged along its length. The domains I, II and III of HSA 
have a net range of -9 , -8 and +2 respectively at pH 
7.0 (Peters, 1985). 
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SUBDOMAIN"A* SUBDOMAIN "B* 
Fig. 2, Topology of a typical domain, shared by suddomain 
A and B. Various helices are shown as hl-hlO. 
(Taken from He and Carter, 1992). 
1« 
Denatiiration: 
HSA is a flexible but stable protein molecule at 
neutral pH. Like many other proteins it can be denatured by 
chemical denaturants like guanidine hydrochloride and urea, 
by heat and by extreme of pH. A number of workers have 
investigated the denaturation of albumin by urea, 
guanidine hydrochloride, and by heat (Tanford, 1968; 
Lapanje, 1969; Johanson et al., 1981., Chemlik and Kalous, 
1982; Shrake and Ross, 1988 a, 1988b and 1990 Khan et al., 
1987; Ahmad and Qasim, (1995). 
Ligemd binding characteristics: 
Albumin has a most outstanding feature of binding a 
diverse set of compounds differing in structure and chemical 
properties. This field has been well reviewed by Lindup, 
1987, Peters, 1985, 1992, Kragh- Hansen, 1981, Fehske et 
al., 1981 and Carter and Ho, 1994. For the majority of 
ligands, serum albumin has been referred as a non-saturable 
carrier (Brodersen et al., 1984). 
Albumin binds several inorganic ions like Ca''"'*", Cu"'"*', 
Ni"*""*", Zn"*"*", Mn"*"'', Co"*"*", Cd"'"'', Au"*" and Al'*"'""'' (Pederson, 1978, 
Hilak et al., 1974; Sarkar, 1983; Peters, 1984; Shaw, 1979; 
1989; Trapp, 1983; Lukasta, et al., 1980) Organic compounds 
(predominantly negative charged molecules) of varying 
structure and nature also bind to serum albumin (Roda et 
16 
al., 1982; Ghiggeri and Queirolo, 1985; Brodersen, 1979, 
Spector and Fletcher, 1978; Lamola and Asher, 1981; Hsia and 
David, 1982). These include some physiologically important 
ligands like bilirubin. Fatty acids etc. (Kragh - Hansen, 
1983, Brodersen and Ebbesen, 1983, Brodersen et al., 1983, 
1984, 1990, Honore and Brodersen, 1984, Berde et al., 1979, 
1984, Lightner et al., 1986, Vorum et al., 1992, Sato et 
al., 1988, Parks et al., 1983, Reed, 1986, Hamilton et al., 
1991) and a large number of extraneous drugs which bind to 
albumin upon their entry into blood circulation. 
These broad spectrum of drugs includes: indomethacin 
(Mason and Mac Queen, 1974, Honore et al., 1983, Ekman et 
al., 1980; Taira and Tecrada, 1985) warfarin (Larsen et al., 
1985, wilting et al., 1980 a, Vorum et al., 1993, 1994, He 
and Carter, 1992), salicylic acid (Taria and Terada, 1985; 
Brodersen, 1974, Brodersen et a.T., 1987), diazepam (Bos et 
al., 1988, Kragh-Hansen, 1983, Wanwimolruk et al., 1983, He 
and Carter, 1992), digitoxin (Brock, 1975, Luckas and 
Demartino, 1969, He and Carter, 1992), phenyl butazone 
(Brodersen, 1974, Honore and Brodersen, 1984, Brown and 
Crooks, 1976), pencillin and its derivatives (Ahlstedt and 
Kristofferson, 1982, Yuvan and Wal, 1988), chlorpheniramine 
(GonzalezJaimenz, 1994), fusidic acid ( Brodersen, 1985), 
Chlorpromazine (Sharpies, 1975, Gabay and Huang, 1974), 
naproxen ( Franssen et al., 1993), ketoprofen (Noctor et 
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al., 1992, Russeva et al., 1994), physostigmine (Whelpton 
and Hurst, 1990), gliclazide (Igaki, et al., 1992), 
camptothecin (Burke and Mi, 1994), tylophorinidine (Dutta et 
al., 1981), valproate (Kober et al., 1980, Brodersen et al., 
1990), sulfaethidole, sulfaphenazole (Brown and Crooks, 
1976; Janssen and Nelen,1976). 
Many organic dyes also bind to serum albumin. They 
include: Congo red (Peters, 1970, Tayyab and Qasim, 1990a), 
bromocresol greem (Reed, 1975; Bush and Reed 1987), methyl 
red (Burkhard et al., 1961), bromophenol blue (Tayyab and 
Qasim, 1990b), Amidoschwarz lOB (Andersen et al., 1978). tri 
and tetra anionic azo dyes. Amaranth, Ponceau 4 and 6R 
(Murakariu, 1991), aniline naphthalene sulfonate (Kolb and 
Weber, 1975, Nerli and Pico, 1994). 
Other biologically important compounds which bind to 
albumin are: tryptophan ( Sollene et al., 1981, Lagercrantz 
et al., 1981, Cheng et al., 1981, Bohney and Feldhoff, 
1992), catecholamine (Powis, 1974) folate (Soliman and 
olessen, 1976), lysolecithins (Nagawa and Nishida, 1973, 
Gul and Smith, 1974), thyroxine (Okabe et al., 1975, Bernard 
et al., 1979, Chang et al., 1981), prostaglandians (Unger, 
1972, Hamberg and Fredholm, 1976, Maclouf et al., 1980), 
steroid hormone (Ryan, 1973, Basset et al., 1977, Romen et 
al., 1975), Hydroxy phenyl azobenzoic acid, HABA (Sakurai 
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and Tsuchiya, 1985). 
In addition to this, albumin binds to microvascular 
endothelium (Schnitzer et al., 1992) and to cibacron blue 
(Ghiggeri and Queirolo, 1985). The cibacron blue-sepharose 
columns are of higher priority, in isolation and 
purification of serum albumin by affinity chromatography. 
Ligand binding regions of albumin: 
At which positions in the albumin molecule are ligands 
bound with a high affinity? How are the binding regions of 
albumin constructed? Extensive research work has been 
carried out to solve this puzzle and been well reviewed by 
Lindup (1987), Kragh-Hansen (1981), Peters (1985), Fehske et 
al., (1981) and carter and Ho (1994). Various commonly 
used methods are: chemical modification (Jacobsen, 1972, 
1976, Roosdorp et al., 1977, Tayyab and Qasim, 1987, 1989, 
Mir et al., 1992, Sakurai and Tsuchiya 1985), fragmentation 
(Feldhoff and Ledden, 1983, Reed et al., 1975, Ledden and 
Feldhoff, 1983, Reed and Baharach, 1983), affinity 
labelling (Jacbosen, 1978, Reed and Mackay, 1985, Jori et 
al., 1980), competitive binding (Shockley et al., 1982, 
Brown and Shockley, 1982, Solene and Means, 1979, Walker, 
1976, 1987, Shaklai et al., 1984) and by interaction between 
one ligand site and other by computing distance, using 
energy transfer (Berde et al., 1979, Hagag et al., 1983j 
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Honore, 1987). 
In addition to this, other means are: thermodynamic 
principles (Jacobsen, 1911, Urien et al., 1994), point 
mutation (Minchiotti et al., 1993) or by using genetic 
variants differing in specificity of binding for a 
particular ligand (Watkins et al., 1993) and , more 
recently by X-ray crystallographic study (Carter and Ho, 
1994). 
Various proposed ligand binding sites/regions of 
albumin molecule are summarized in Table II. (Kragh-Hansen, 
1981; Peters, 1985 and Carter and Ho, 1994). 
A single metal binding site has been characterized at 
N-terminus of albumin (Glennon and Sarkar, 1982, Lussac and 
Sarkar, 1980 and 1984) according to the model of Kragh-
Hansen (1981) and Peters (1985). The binding region/site of 
Cu"*"*" is believed to be at His-3 (Sarkar, 1983, Peters, 
1984). Recently, Carter and Ho (1994) have classified 2 
distinct metal binding sites. One site has been referred as 
site V, for Au, Ag, Hg, Cd etc. (Shaw, 1989) and another, 
site VI (N-terminus) is chiefly for Cu"*"^  and Zn. The 
involvement of Cys-34 has been shown in site V. 
According to Kragh-Hansen (1981) and Peters (1985) both 
amino acids, tryptophan and thyroxine share a common binding 
site on albumin with small chain fatty acids and drugs of 
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TABLE - II 
SCHEME FOR BINDING REGIONS LOCATED ON HSA 
Bindinq Hiah aff initv bindina site 
region/site Kragh-Hansen(1981) Peters(1985) 
I Long chain fatty 
acids 
II Trytophan/Thyroxine 
III Bilirubin / dyes 
IV Metals (ions) 
V Haemin 
VI Drugs(Sudlow class I) 
Long chain fattyacids 
(172 73 74") 
Tryptophan/Thyrox i ne 
Bilirubin 
Metals (ions) 
Haemin 
Others (drugs) 
* Small organic ligands (I & II) in subdomains IIA, 
acids in subdomain IB, IIIA, III6. 
Carter and Ho(1994)* 
Small organic ligands 
Small organic ligands 
Long chain fatty acids 
Long chain fatty acids 
Metals (Cys-34) 
Metals (N-terminus) 
IIIA;Long chain fatty 
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Shudlow class II (King and Spencer, 1970, Sjodin, 1977, 
Fehske et al., 1979, Kragh Hansen, 1981, 1983, Sollene and 
Means, 1979, Wanisoimolruks et al., 1983; Phuong-Kgugen et 
al., 1982). The Sudlow class II drugs include dia2epain, and 
naproxen). The expected location of this site is in between 
198-582 of BSA (Peters and Feldhoff, 1975) or 182-585 of 
HSA (Sjodin, 1977), while Lys-414 of HSA has been 
implicated in thyroxine binding site (Brown and Shockley, 
1982). In their model , Carter and Ho (1994) have suggested 
subdoraain IIA as the binding site of tryptophan. 
A separate binding site (high affinity) for bilirubin 
on albumin molecule has been proposed by Kragh-Hansen (1981) 
and Peters (1985). Various fragments of albumin i.e. 1-
306, 1-385 ( Reed et al., 1975). 1-387 and 49-308 (Feldhoff 
and Ledden, 1983) have shown their affinity towards 
bilirubin. Meanwhile Lys-240 of HSA has been shown as a 
critical residue for bilirubin- albumin niteraction 
(Jacobsen, 1978). Photocoupling of bilirubin- albumin have 
shown the presence of bilirubin binding site in 187-397 
(Jori et al., 1980). Another affinity labelling study has 
proposed that Lys-195 in HSA is critical. (Reed and Mackay, 
1985). While the distance between Trp 214 and site is about 
27 A° (Berde et al., 1979, Peters, 1985). The studies with 
albumin Herbon ( a new genetic variant of HSA with Lys 240 
•^  Glu] has ruled out the possible involvement of Lys-240 in 
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bilirubin albumin interaction (Minchiotti et al., 1993). 
Moreover, Watkins, et al., (1993) has also supported it. 
Although the binding site is not confined but the possible 
role of one-two lysine residues in bilirubin binding cann't 
be ruled out (Tayyab and Qasim, 1987, Mir et al., 1992). 
Carter and Ho (1994) believe that bilirubin is primarily 
bound to the site within IIA. 
Serum albumin contains several fatty acid binding 
sites. Some are strong and some are weak and they are 
distributed over all the three domains (Peters, 1985). 
Recent crystallographic studies have revealed three major 
binding sites i.e. IB, IIIA and IIIB (Carter and Ho, 1994). 
Drugs of Sudlow class I (Sudlow et al., 1975), 
including Warfarin, aspirin and several sulfonamides share 
a common binding site (Kragh-Hansen, 1981, Peters, 1985). 
Various studies like CNBr fragmentation, 124-298 ( Sjoholm 
and Ljungstedt, 1973), Trp 214 and warfarin interaction 
(Fehske et al, 1981) and specific acetylation of Lys-199 of 
HSA (Walker, 1976) have been attempted to locate this 
binding of albumin. 13C NMR spectroscopy (Gerig et al, 1981) 
indicates that aspirin bidning site is well exposed to 
solvent. 
In their recent model. Carter and Ho (1994) have 
classified 2 binding sites namely I and II for small organic 
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ligands in domain IIA and IIIA. He and carter (1992) has 
proposed that the binding sites are specialized hydrophobic 
pockets. The pocket in IIA is lined with Leu 203, Phe 211, 
Try 214, Ala, 215, Leu, 219, Phe 223, Leu 234, Val, 235, Leu 
238, Val 241, Leu, 260, Ala 261, H e 264, H e 271, Leu 275 
and H e 290 and in IIIA with Pro 384, Leu 387, H e 388, Phe 
395, Leu 407, Val 415, Val 418, Leu 423, Val 426, Leu 430, 
Val 433, Leu 453, Val 456, Leu, 457, Leu 460, Val, 473, and 
Phe 488. These hydrophobic residues form a focal point 
around Lys 199 and His 242 in IIA and Tyr 411 and Arg 410 in 
IIIA. As per this model Sudlow class I drugs bind in IIA 
while II class Sudlow drugs in subdomain IIIA. Various 
binding sites on human serum albumin are shown in Fig. 3. 
Interaction of variotis drug and bilirubin with albusin: 
The affinity of drugs to albumin are in the range of 
log Ka = 4 to 6 and for bilirubin and other fatty acids are 
of log Ka=7 to 8. The affinity of selected drugs and 
bilirubin is given in Table III. 
Free bilirubin is cytotoxic and neurotoxic. It renders 
nontoxic upon complexation with albumin (Brodersen, 1979, 
Peters, 1985). Jacobsen (1969) proposed that albumin has a 
strong binding site (Ka=1.4xl0^~^) and two weaker sites 
(Ka=5xl0^ M~^) for bilirubin. Under physiological conditions 
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Fig. 3 Various ligands bindings are shown on stereo view 
of human serum albumin. The binding sites has 
been determined cystallographically (He and 
Carter, 1992) except for those, marked with 
asterisks. 
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TABLE - III 
BINDING CONSTANTS FOR VARIOUS LIGANDS WITH RSA 
Ligand 
Bilirubin 
Ka,* (M~^) Reference 
Linoleate 
Oleate 
Palmitate 
Indomethacin 
Salicylic acid 
1.4xlo: 
5.0x10; 
6.4x10 
1.2x10 
7.9x10; 
2.6x10 
6.0x10, 
3.0X10-
i.sxioj 
2.5X10-
i.sxioj 
2.1x10; 
2.2x10-
8 
8 
Jacobsen (1969) 
Jacobsen (1977) 
Berde et al. (1979) 
Berde et al. (1984) 
Specter and Fletcher (1978) 
Specter and Fletcher (1978) 
Specter and Fletcher (1978) 
Hansen and McQueen (1974) 
Ekman et al. (1980) 
Honore et al.(1983) 
Brodersen 
Taira and 
Brewn and 
et al.(1987) 
Terada (1985) 
Creeks (1976) 
Phenyl butazone 
Warfarin 
Diazepam 
Digitexin 
Tylephrinidine 
Ch1erprema z i ne 
2.5x10^ 
1.9X10^, 
1.65X1Q-
2.5X10^ 
2.2X10^ 
4.3X10* 
6.9X10* 
5X10* 
4.2X10* 
1.9X10^ 
Brewn and Creeks (1976) 
Verum et al. (1973) 
Larsen et al.(1985) 
Sudlew et al. (1975) 
Wilting et al.(1980a) 
Brecks (1975) 
Lukas and DeMartina(1969) 
Datta et al. (1981) 
Gaby and Huang (1974) 
Sharpies (1975) 
* Fer primary binding sites. 
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the concentration of bilirubin is low and even primary 
binding site is not fully saturated. In hyperbilirubinemic 
neonates however, the primary site may be completely 
saturated. The weaker sites are not capable to prevent the 
entry of free bilirubin into the brain, where its deposition 
ultimately causes development of kernicterus (Brodersen, 
1979, Newman and Klebanoff, 1993). Due to the insignificant 
role (if any) of these two weaker binding sites in the 
detoxification of bilirubin, the characterization of 
primary binding has been attempted. 
In order to investigate the role of amino acid and /or 
site involved in this interaction, several modification, 
affinity labelling etc. studies were performed (See " ligand 
binding regions of albumin" section). 
Despite disagreement regarding the identity of lysine 
residue(s), the participation of one or two lysine residue 
in this interaction has not been challenged. Studies from 
our laboratory, based on selective modification of lysine 
(s) have suggested that the lysine residue (s) involved in 
this interaction are buried in the protein and are not 
accessible to aqoues environment in native protein (Tayyab 
and Qasim, 1986, 1987, Mir et al., 1992, Fazili et al., 
1993). The similar results have been also shown by Islam et 
al. (1994), Tayyab et al.(1995) with modified derivatives of 
goat serum albumin. On the basis of thermodynamic data and 
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ionic strength dependency of this interaction, it appears 
that the forces are mainly enthalpy driven and hydrophobic 
interactions are of lesser significance (Jacobsen, 1977). 
Jacobsen and Brodersen (1983) proposed that bilirubin 
molecule exists in a more expanded conformation at its 
binding site. The normal hydrogen bonded pattern is lost 
(Lightner et al., 1986) and probably the two negative 
charges, contributed by carboxyl group of bilirubin are 
neutralized by two positively charged groups of albumin. 
Jacobsen and Brodersen (1983) have further stated that 
this interaction is biphasic involving a fast step followed 
by slow relaxational changes which lost for a period of 
500 sec. The fast step's events are unknown while second 
step involve certain conformational changes. In addition to 
this Tayyab and Qasiro (1987) have proposed that bilirubin 
binds loosely at surface of protein near primary binding 
site which may be followed by opening of hydrophobic pocket 
in which bilirubin molecule slides and reaches its high 
affinity binding site in protein molecule. Indeed, the 
bilirubin-albumin interaction seems as yet poorly 
understood and needs further investigation. 
Serum albumin serves as a non-saturable carrier, with 
one high affinity and several lower affinity sites for drugs 
(Brodersen et al., 1984, Peters; 1985, Lindup, 1987). 
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Initially, Sudlow (Sudlow et al., 1976) has classified drugs 
into three class, i.e. Sudlow I (warfarin groups with 
aspirin, naproxen and sulfonamide), Sudlow II (Diazepam 
groups with ibuprofen etc) and Ilird as Digitoxin site. 
Binding sites for certain drugs on albumin have been 
characterized so far (see " ligand binding regions of 
albumin" section) are of warfarin, salicylic acid diazepam 
etc. Binding sites of various drugs have been located 
successfully by X-ray crystallographic techique (He and 
Carter, 1992). These drugs with their binding location in 
parenthesis are: warfarin (IIA), diazepam, digitoxin, 
clofibrate, ibuprofen and 3' azido-S deoxythimidine (IIIA) 
and derivatives of salicylic and like, aspirin, 5-
iodosalicylic acid, 3^5, diiodosalicylic acid with 2,3,5-
triiodobenzoic acid (in IIA-IIIA subdomains). 
A significant variation in affinity constants has been 
observed (see TAble III). These binding affinities have 
been studied primarily by equilibrium dialysis or 
spectroscopic methods. Data from such studies are generally 
analyzed by Scatchard method (Lindup, 1987) assuming that 
the binding sites of a similar nature are of the same class 
and interact with drugs independently without any mutual 
interaction either when they are free or are occupied by 
other. Later on Taira and Terada (1985) introduced specific 
and nonspecific model of binding to justify the Scatchard 
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model. More recently, a new procedure for analysing drug -
HSA binding data has been given (Vorum et al., 1993, 1994) 
to calculate the binding affinity of primarily and 
following sites accurately. 
Besides all this, the molecular basis of drug albumin 
interaction is uncertain. 
Drug induced bilirubin displacement: 
Kernicterus is generally caused by precipitation of 
insoluble bilirubin in brain cells (Brodersen 1979).This 
pigment is transferred from blood plasma to cells. The 
tendency of precipitation depends upon the ratio of 
unconjugated plasma bilirubin concentration to the 
concentration of reserve bilirubin for binding of bilirubin 
and is increased when part of the albumin is occupied by 
competitive binding of drug (Brodersen et al., 1983, Stern, 
1984) An outbreak of fatal kernicterus in icteric infants 
treated with sulfisoxazole was reported by Silverman et 
al.,(1956) and was explained as due to binding of drug to 
albumin displacing bilirubin into central nervous system 
(Odell, 1959, Levine, 1982, Cashore and Oh, 1982, Bratlid, 
et al., 1984a). About 150 durgs have been tested by Danish 
scientist, Rolf Brodersen for thier bilirubin displacement 
effect. Majority of drugs have shown thier positive 
response towards bilirubin displacement (Brodersen, 1978). 
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Various sulfonamides drugs have been identified as a 
strong bilirubin displacer (£5ie and Levy, 1979b, Jarnerot et 
al., 1981, Brodersen, 1978, Bratlid et al., 1984b, Cashore 
et al., 1983, Brodersen et al., 1983, Walker, 1987). Various 
drugs, tested for their displacement risk are: salicylic 
acid ((^ ie and Levy, 1979 Brodersen & Ebbessen 1983) 
gentamycin (Brodersen et al., 1983, Brodersen and Ebbessen, 
1983), chlorpromazine, ampicillin (Brodersen and Ebbessen, 
1983), indomethacin (Lam et al., 1990, Brodersen and 
Ebbessen, 1983, pencillin (Fink et al., 1988), pancuronium 
(Robertson and Karp, 1982), cephalosporins (Robertson et 
al., 1988), furosemide (Peterson et al., 1980, Cashore et 
al., 1983) fusidic acid (Brodersen, 1985), diazepam 
(Maruyama et al., 1985) cifmonoxine (Onks et al., 1991), 
tazobactam (Karp, 1990) and even Chinese herb, berberine 
(Chan, 1993). 
Peroxidase method (Jacobsen and Wennberg, 1974) has 
been for majority of drug induced bilirubin displacement 
studies (Robertson et al , 1991). A rough sketch of drug 
induced biliribuin displacement from albumin has been 
discussed by Brodersen et al (1983). With a competitive 
nature of displacement in general. The binding affinity of 
drugs to albumin (10^-10^) is generally much lower as 
compared to the affinity of bilirubin (10 ). Incomplete 
knowledge of binding site /nature makes it difficult to 
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explain the complex displacement behaviour of bilirubin by 
most drugs. 
Chemical Bodification: 
Chemical modification of proteins is often employed to 
identify the functional group involved at the active site 
(Glazer et al., 1975, Means and Feeney, 1971, Stark, 1970, 
Habeeb, 1970. Mir et al., 1992, Islam et al., 1994, Tayyab 
et al., 1995). Extensive modification of lysine residues of 
proteins have been performed earlier with an aim to 
understand the influence of such modification on 
physicochemical and biolgocial properties of protein (Jonas 
and Weber, 1970, Nakagawa et al., 1972, Khan and Surolia, 
1982, Ansari et al., 1975, Qasim and Salahuddin, 1975, 
Tayyab and Qasim 1987, 1989, Batra et al., 1990, Mir et 
al., 1992, Tayyab et al.^ 1995). However, attempt has been 
made in our laboratory to modify buried lysine residues of 
BSA by double modification technique (Mir et al., 1992). 
Also, it has been proposed earlier that these buried lysine 
residues are 'critical' for bilirubin-albumin interaction 
(Mir et al., 1992). 
In order to explore the molecular basis of the 
interaction of various ligands (structures are shown in 
Fig. 4) to serum albumin, the fluorescence quenching 
technique has been used under varying experimental 
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CH3O 
CH2CH2CH2N(CH3)2 
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INDOMETHACIN CHLORPROMAZINE 
COO" 
OH 
SALICYLIC ACID 
Fig. 4 . S t ructures of various l igands . 
33 
condition i.e., temperature, pH and ionic strength. 
Five carbamylated preparations of HSA have been 
prepared with selective modification of exposed and buried 
lysine residues, using conventional and double modification 
technique. In addition to this a novel technique of 
fluorescence enhancement has been developed to study the 
drug induced bilirubin displacement from albumin by certain 
drugs. 
EXPERIMENTAL 
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A. MATERIALS: 
1. Proteins and enzyne: 
Human serum albumin, fraction V (Lot Nos. 47 F-9338 and 
76F-93222), Ovalbumin (Lot No. 23F-8175), o<j 
chymotrypsinogen (Lot No. lllF-8055), V -globulin (Lot No. 
89B-1390) and tyrosinase (Lot No. 29C- 9640) were purchased 
from Sigma Chemical Company, USA. 
2.Ligands used in interaction studies: 
Indomethacin (Lot No. 60H-0448) and chlorpromazine (Lot 
No. 112 H 0125) were obtained from Sigma Chemical Company, 
USA. Salicylic acid was a product of Central Drug House, 
India. Bilirubin was purchased from Reanal, Hungary. 
3. Reagents used in Chencial •edification: 
Citraconic anhydride, guanidine hydrochloride and 
trinitrobenzene sulfonic acid (TNBS) were obtained from 
Sigma chemcial company, USA. Potassium cyanate and ninhydrin 
were procurred from Koch-Light laboratories Ltd., England. 
Ascorbic acid, methyl celloslove and sodium dodecyl sulphate 
were from BDH, England. Hydrindantion was prepared by 
reducing ninhydrin with ascorbic acid as described by Moore 
and Stein (1954). 
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4. Gel Chromatographic media: 
Sephacryl S-200 HR with a bead diameter 25-75 u (Lot 
No. 73H-0540) and blue dextran 2000 were the product of 
Sigma Chemical Company, USA. 
5. Reagent used in electrophoresis: 
Dimethyl dichlorosilane and commassie brilliant blue R-
250 were purchased from Sigma chemical company, USA. 
N,N,N',N' tetraraethylene diamine and bromophenol blue were 
obtained from BDH, England and PPH, Poland respectively. 
Riboflavin was procured from E.Merck, Germany. Acrylamide, 
N,N' methylene bis acrylamide, ammonium persulfate,tris-
(hydroxy methyl amino methane) glycerol, sucrose, glycine, 
chloroform, methanol and acetic acid were the product of 
Qualigens Fine Chemicals, India. 
6. Other reagents: 
Analytical grade samples of sodium acetate, sodium 
chloride sodium, phosphate monobasic and dibasic, sodium 
carbonate, sodium hydrogen carbonate, sodium tungstate, 
sodiummolybdate, soidum potassium tartarate, sodium 
hydroxide, sodium azide, copper sulphate, ethylene diamine 
tetracaetic acid, lithium sulphate, potassium permanganate, 
potassium dichromate, potassium fericyanide, orthophosphoric 
acid, hydrochloric acid, sulfuric acid and liguid bromine 
36 
were taken. 
7. Miscellaneous: 
Dialysis sacks of different flat width (25 mm, Lot No. 
82H-0050 and 43 mm. Lot No. 92H-0291) were purchased from 
Sigma Chemical Company, USA. Millipore filter units of pore 
size 0.45 um and 13 mm diameter - Millex - HV23 (Lot No. 
H3HM-99566) were obtained from Millipore products Division, 
USA. Whatman filter paper No. 1 (12.5 cm diameter) was a 
product of Whatman Ltd., England. Solid glass beads (5 mm 
diameter) were from Kimble Resistant Glass, USA. Buffer 
tabelets of pH 4.0, 7.0 and 9.2 were obtaiend from Qualigens 
Fine Chemicals, India. 
All glass distilled water was used throughout these 
studies. 
B. Methods: 
1. pH BeasureKents: 
Measurements of pH were carried out on an Elico pH 
meter, model LI-IOT, using PPC Elico combined glass 
electrode type, CL-51. Before pH measurements, the pH meter 
was routinely caliberated by standard buffers of pH 4.0, 
7.0 and 9.2 for measuring the pH values in acidic, neutral 
and in alkaline pH range respectively. 
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2. Optical •easurenents: 
(a) Light: absorption measurenents: 
Light absorption measurements in the ultraviolet as 
well as in visible region were performed on Shimadzu 
double beam spectrophotometer, model UV-150-02 by using 
matched silica cells of 1 cm pathlength. 
(b) Fluorescence neasurenents: 
Fluorescence measurements were made on a Shimadzu 
spectrofluorophotometer, model RF-540 equipped with a data 
recorder , model DR-3, using quartz c e l l of 1 cm pathlength. 
The other accesssor ies a t tached to fluorophotometer were a 
water jacketed c e l l holder equipped with a mini magnetic 
s t i r r e r (Hellma c u v - o - s t i r , model 333) and a c o n s t a n t 
temperature water c i r c u l a t o r , TB-85. 
3 . Detenunation of protein concentration: 
P r o t e i n c o n c e n t r a t i o n was determined e i t h e r by t h e 
method of Lowry e t a l . , (1951) using human serum albumin as 
standard or by spectrophotometric method. 
(a) Method of Lowry e t a l , (1951) : 
This mehtod involves the use of two reagen ts , namely, 
Folin-phenol reagent and copper reagent. 
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(i) Preparation of Folin-Phenol reagent: 
Folin phenol reagent was repared according to the 
method of Folin and Ciocalteu, 1927. To a two litre flat 
bottemed flask, wrapped with a black carbon paper were added 
100 g of sodiin tungstate, 25g of sodium molybdate, 50 ml of 
85% orthophosphoric acid, 100 ml of 11.4 N hydrochloric acid 
and 700 ml of water. The mixture was refluxed for about 10 
hours. Afterwards 150 g of lithium sulfate, 50 ml of water 
and few drops of liquid bromine were added. Fianlly the 
mixture was heated without condenser for half an hour to 
remove excess bromine . After cooling, total volume was 
made upto one litre with water. This stock was filtered and 
stored in an amber colored bottles. The stock reagent was 
diluted four times with water before use. 
(ii) Preparation of copper reagent: 
Stock solution of 4% (W/v) sodium carbonate, 4% (W/v) 
sodium potassium tartarate and 2% (W/v) copper sulfate were 
preapered. The solutions wre mixed in the ratio of 100:1:1 
respectively. The reagent was filtered before use. 
(iii) Procedure: 
An appropriate volume of protein solution (0.1-1.0 ml) 
was taken in a test tube and total volume was made up to 1.0 
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ml by adding requisite amount of water or suitable buffer. 
Then 5.0 ml of freshly prepared copper reagent was added 
and mixed well. After 10 minutes, 1 ml of diluted folin-
phenol reagent was added and the contents were mixed well. 
Color intensity was recorded after 30 minutes at 700 nm, 
against a blank prepared in the same way except that it 
contained only water or buffer and no protein. 
For quantification caliberation plot between protein 
(HSA) concentration and absorbance was obtained. These data 
were analysed by least square method and fitted into the 
straight line equation: 
Y = 1.66 X + 0.007 (1) 
where Y is the absorbance at 700 nm and X is the amount of 
protein in mgs. 
(b) SpectrophotoBetric Method: 
The absorbance of protien solution was measured at 279 
nm against appropriate blank. The concentration of protein 
(HSA) was calculated by using specific extinction 
coefficient (E^*^ ^ j^ ) value of 5.31 (Edward et al., 1969). 
Scattering corrections when needed, were done by 
extrapolating absorbance value in 360-330 nm region to the 
absorbing region. 
(4) Gel ChroKatography: 
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Sephacryl S-200 HR was used as a gel chromatographic 
media. The gel was washed several times with water and 
deaerated by heating the contents on a boiling water bath 
for half an hour. The fine paticles of the gel were removed 
by decantation. This process was repeated 5-6 times till the 
gel was free from fines. 
Before packing, a glass column (about 110 cm long) was 
thoroughly washed with detergent, chromic acid and finally 
with water. Column was mounted vertically in sturdy and 
vibration free position and its narrow bore was connected to 
a latex tubing to regulate the flow rate. The radius (r) of 
the column was determined at three different places of the 
column. Volume of water corresponding to 3 cm height in the 
column were collected in three preweighed weighing bottles. 
The volume of water (v) corresponding to the height (h) of 
3 cm was then determined by dividing the weight (w) of the 
water by its density (p) at the particular temperature. The 
radius (r) of the column was calculated as follows: 
V sAr^ h (2) 
T^ r^ h = w/j> (3) 
r = (w/p7rh)V2 (4) 
:w/j)7rh 
The total volume of the column (Vt) was calculated by 
following realtionship : 
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Vt =^r2i (5) 
where 1 denotes the total bed length of the column. 
A small amount of glass wool, previously boiled in 
water was placed at the bottom of the column and its 
surface was covered with glass beads. One fourth volume of 
the column was filled with operating buffer. An extension 
column was connected to the column and then degassed gel 
slurry was carefully poured into the column. 
The gel was left to settle under garvity overnight at 
room temperature. When the gel formed a smooth layer, the 
outlet was opened with an initial flow rate of 5 ml per 
hour. As the gel settled down, the flow rate was increased 
gradually to a value slightly higher than that to be 
employed during operation. The extension column was 
detached and column was equilibrated by passing three bed 
volumes of 60 mM sodium phosphate buffer, pH. 7.0. I 0.15 
containing 0.02% sodium azide as preservative. In addition 
to this column (100.5 x 2.4 cm) another sephacryl S-200 HR 
column (62x1.68 cm) was also packed in the same fashion and 
was used for analytical purposes. 
For sample applicaiton, the operating buffer above the 
column bed was first drained off and the sample was then 
applied slowly along the sides of the column. The stopcock 
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was then opened slowly and the sample was allowed to pass 
down the upper surface of the gel. When all the protein 
sample had passed into the gel the eluent buffer was 
applied. The column was operated at a flow rate of 20-25 ml 
per hour. Fraction of 1 ml close to protein peakes and 5 ml 
elsewhere were collected and monitored for protien either 
by the method of Lowry et al., 1951 or by measuring 
absorbance at 280 mm. 
The homogeneity of packing was checked by passing a 
band of 0.2% solution of blue dextran 2000 through the 
column. The elution volume of blue dextran yielded the void 
volume (VQ) of the column. The internal volume (Vj^ ) of the 
column was obtained by subtracting the void volume from the 
elution volume of a small molecular weight compound like 
potassium ferricyanide (Andrens, 1970). The elution volume, 
Vg, of a protein sample was obtained from its elution 
profile. The volume of sample was 1% of the total gel 
volume. Marker proteins used for calibration with their 
stokes radii in parenthesis were: ©C chymotrypsinogen (2.24 
nm) ovalbumin (2.73 nm), tyrosinase (4.23 nm) and and X -
globulin (5.30 nm). 
Stokes radii were determined by the method of Laurent 
and killander (1964) and Ackers (1967). The distribution 
coefficient (K^) and avialable distribution coefficient 
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(Kgy) ware calculated by following relationships: 
V - V 
e o , ^ 
Kd = (6) 
Vi 
Ve - VQ V = (7) 
Vt - Vo 
The data were treated according to equaiton given by 
Laurent and Killander (1964) 
(-log kay)V2 = Ar + B (8) 
where A and B were the calibration constants. 
For calculation of stokes radii by Ackers (1967) 
method,the following relationship was used. 
r = ao + bo erfc"^ k^ j (9) 
where aQ and bQ were the calibration constants. 
Another hydrodynamic parameter, frictional ratio f/fo 
was calculated by folowing relation : 
f/fo = r/ (3 V2 m/4AN)^/^) (10) 
where r is the stokes radius, V2 is the partial specific 
volume reported to be 0.733 for HSA (Charlwood, 1961), M is 
the molecular weight of protein and was taken to be 69000 
for HSA (Peters, 1985) and N is the Avagadro's nuflber (6.023 
X lO^ -* per mole). 
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6. Polyacrylamide gel electrophoresis: 
Polyacrylamide gel electrodphoresis was performed on 
rectangular glass plates (10.8 x 10.8 cms) in 4.95 mM tris 
38 mM glycine buffer, pH 8.2 by he standard procedure 
(Davis, 1964). 
Small pore solution was prepared as described by 
(Davis, 1964). It was poured in the space between the two 
plates to 3/4 height of the plates. The contents of small 
pore solution were: 10% (W/V) acrylamide, 0.26% (W/V) N,N' 
methylene biscacrylamide, 0.05% (V/V) N,N,N',N' 
tetramethylethylene diamine, 0.05% (W/V) ammonium 
persulfate, 7.26% (W/V) tris and 0.812% (V/V) cone. Hcl. 
After coating a water layer over small pore solutin, the 
contents were allowed to {)olymeri2e at room temperature. 
Finally the water contents wre drained off and remaining 
(1/4) height of the plates was filled with large pore 
solution containing 3.75 (W/V) acrylamide, 0.1% (W/V) N,N' 
methylene bisacrylamide, 0.05% (V/V) N,N,N',N' tetramethyl 
ethylene diamine, 0.0005% (W/V) riboflavin, 20% (W/V) 
sucrose, 1.5% (W/V) tris and 1%(V/V) of cone. Hcl. A comb 
was then placed at the notch on the upper end of plates. 
The large pore solution was photopolymerized under 
fluorescent source for 15 minutes. After polymerization the 
comb was removed and wells were rinsed with sample buffer. 
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The smaples were prepared by using 0.3 rag of protein in 
1 ml of electrophoresis buffer containing 20% (W/V) 
sucrose and 0.01% (W/V) bromophenol blue. 
The bracket and claraps were removed and the plates were 
fitted in Broviga mini vertical slab gel electrophoresis 
unit by placing the lower end of the plates in lower tank 
of unit, filled with electrophoresis buffer. The sides of 
plates were held in place in the unit with the help of two 
clamps. About 20ul of the sample solution was applied in 
each well with the help of a narrowtipped raicropipette. The 
remaining space inside the wells were filled with buffer. 
After filling the upper tank of unit with buffer an anodic 
current of 1 mA per well was passed till the bromophenol 
blue passes down across the large pore gel. Finally the 
current per well was increased to 1.5 mA. The 
electrophoresis was continued till the bromophenol blue 
(tracking dye ) front had migrated to nearly 3/4 of the 
small pore gel. After electrophoresis, gel was taken out and 
stained overnight in 0.1% (W/V) commassie brilliant blue 
R-250 prepared in 42% (V/V) methanol and 17% (V/V) acetic 
acid. Initially, the destaining was performed with 30% (V/V) 
methanol and 10% (V/V) acetic acid and finally with 7% 
(V/V) acetic acid. 
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The relative mobility, riti was obtainined by: 
distance travelled by protein band 
r^ = (11) 
distance travelled by tracking dye 
6. Preparation of HSA monomer: 
Human serum albumin monomer was obtained by size 
exclusion gel chromatography of commercial HSA preparation 
on a sephacryls-200HR column (100.5x2.4 cm), quilibrated 
with 60mM sodium phosphate buffer, pH 7.0 containing 0.02% 
sodium azide. Through out this study, the monomeric 
preparation was used and will be termed HSA hereafter. 
7. Preparation of drug solutions: 
Stock solution of various drugs were prepared, as 
mentioned below: 
(a) Stock indomethacin solution: 
One hundred milligram of indomethacin was dissolved in 
1 ml of methanol, the final volume was made upto 100ml 
with 55 nM sodium phosphate buffer, pH 7.0 and I 0.11. The 
concentration was determined spectrophotometrically by using 
molar absorption coefficient of 6290 M*"^ cm""^  at 319 nm. The 
solution was stored at 4°c. 
(b) Stock salicylic and solution: 
One hudred milligram of salicylic acid was dissolved in 
47 
100 ml of 55 inM sodium phosphate buffer, pH 7.0 and I 0.11. 
the concentration was determined spectrophotometrically by 
using molar absorption coefficient of 3530 M~ cm" at 295 
nm. The solution was stored at 4 C. 
(c) Stock chlorpromazine solution: 
Ten milligrams of chlorpromazine was dissolved in 100 
ml of 55 mM sodium phosphate buffer, pH 7.0 and I 0.11. The 
concentration was determined spectrophotometrically by 
measuring the absorbance at 305 nm. The absorbance 
mesasurements were repeated 5-6 times and it was found to 
be 0.25 for a 1% drug solution. The chlorpromazine solution 
was prepared fresh. 
Each stock solution was filtered before use. Further 
dilutions were made from these stock solutions. 
8. Ultraviolet absorption spectral Measurements: 
The ultraviolet absorption spectra of various drugs 
were recorded in 55 mM sodium phosphate buffer, pH 7.0 and I 
0.11 at room temperature in the wavelength 240-360 nm on a 
Shimadzu double beam spectrophotometer, model uv-150-02. The 
durg concentrations were 10 ug/ml. 
9 , Fluorescence •easureaents: 
The fluorescence emission spectra of 
these drugs were recorded in 55 mM sodium phosphate buffer, 
pH 7.0 and I o.ll at 28°c on a shimadzu 
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spectrofluorophotoTaeter, roodel R-540. The excitation 
wavelength values of 320, 295 and 305 were used for 
fluorescence emission spectral measurements to indomethacin, 
salicylic acid and chlorpromazine respectively. The drug 
concentration was 10 ^ g/ml. 
10. Drug-albunin interactloin: 
The interaction of three chemically and structurally 
different drugs namely, indomethacin (an anti-inflamatory 
drug)salicylic acid (an analgesic drug) and chlorpromazine 
(an antipsychotic agent) with human serum albumin was 
studied in detail by fluorescence quench titration method. 
At preliminary level, a pilot experiment was designed to 
explore the applicability of fluorescence quench titrattion 
method in this study, as earlier reported with bilirubin-
albumin interaction (Levine, 1977, Tayyab and Qasim, 1989). 
These interaction studies were performed under varying 
conditions of temperature, ionic strength and pH. 
Fluorescence quench titration was performed in a 
discontinuous manner. A fixed amount of protein (HSA) was 
taken in a series of test tubes and increasing amounts of 
drug solution were added to it. The final volume was made 
to 5.0 ml by adding appropriate amount of desired buffer. A 
protein solution (as a blank) was also prepared in the same 
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fashion except that it contained only protein and buffer but 
no drug. Fluorescence measurements were made on a Shimadzu 
spectrofuorophotometer, model RF-540 equipped with a data 
recorder DR-3. The other accessories attached with 
fluorometer were a water jacketed cell holder equipped with 
a mini magnetic stirrer and a constant temperature water 
circulator device, model TB-85. The tubes were placed in 
thermobath and measurements were made after 10 minutes. The 
solutions were stirred continuously by Cuv-0-stir device. 
The fluorescence emission spectra were recorded in the 
wavelength range 300-450 nm. Other operative conditions of 
fluorometer were: 
Excitation wavelength = 284 or 275 nm 
Oridinate scale = X2 
Abscissa Scale = X2 
Slit (excitation) = 5 nm 
Slit (emission) = 5 nm 
Scan speed = Very fast 
Sensitivity = High 
11. Analisis of drug-albumin interaction data: 
The drug-albumin interaction data were analysed either 
by the method of Levine, 1977. the computer fitting of the 
data was performed according to the method of Vorum et 
al., (1993). 
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(a) Hethod of Levine, (1977); 
The fluorescence intensity at emission maxima of 
protein, 340 nm was transformed into relative fluorescence 
by taking the fluorescence of the drug free protein solution 
to be 100. A graph was plotted between relative fluorescence 
and drug/albumin molar ratio. A least squares analysis of 
the initial linear points of the graph was used to 
determine the maximal quench (m) from the following 
relationship: 
F = FQ-mR (12) 
where F is the fluorescence at drug to albumin ratio (R) and 
FQ is the fluorescence of protein at zero concentration of 
drug. Therefore for the first binding site (R=1.0), the 
maximal quench (m^) was calculated by following equation: 
Fj = Fo-mi (13) 
m^ = FQ-FJL (14) 
where F^^ is the fluorescence observed when one molecule of 
drug is bound to an albumin molecule. 
Using those points showing upward deviation from 
straight line behaviour, the fractional quench, Q was 
determined at each drug/albumin molar ratio (R) with the 
help of following relationship: 
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FQ - F FQ - F (15) 
m^ Fo - F^  
Fractional quench, Q is linearly related to binding, thus; 
[ Drug - Alb ] 
Q = (16) 
[ Alb]^ 
where [Drug-Alb] is the concentration of albumin bound to 
drug and [Alb],j, is the total albumin concentration. 
Then the unbound drug, and unbound albumin, [Alb] are: 
or 
and 
or 
[Drug] 
[Drug] 
[Alb] 
[Alb] 
= 
= 
= 
= 
= 
[Drug]rp 
[Drug]^ 
[Alb],r 
[Alb]^ 
— 
-
-
-
(1-Q) [Alb]^ 
[Drug-Alb] 
Q[Alb]T 
[Drug-Alb] 
Q[Alb]T 
(17) 
(18] 
(19) 
(20) 
(21) 
Using the assoication constant, ka equation: 
[Drug - Alb] 
ka = (22) 
[Alb][Drug] 
Substituting with equations 16-21, 
Q [Alb]m 
J^a =r — «___—____i (23) 
(l-Q)[Alb]T ([Alb]T-Q]Alb]T) 
or 
Q 
(1-Q)([Drug]T/[Alb]T-Q)[Alb]^ 
(24) 
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Since ratio (R) is given by 
R = [ Drug ],p/[ Alb ] T (25) 
Then 
Q 
ka = (26) 
(1-Q)(R-Q) [Alb]T 
The data were analysed for the determination of 
association constant and capacity, by utilizing the 
Scatchard equation (Scatchard, 1949). The fianlly 
transformed Scatchard equation is : 
[Drug-Alb] [Drug - Alb]f(c\ 
nka = = (27) 
[Alb]rp [Drug][Alb],p 
or 
Q Q 
nka - kaQ = = (28) 
[Drug] [R-Q] [AlbJT 
where n is the binding capacity. 
The least squares analysis of the plot between Q and 
Q/[Drug3 yielded the association constant and the binding 
capacity of drug for serum etlbumin. 
(b) Analysis of Drug binding data according to Vorvm et al. 
(1993): 
The titration data for the interaction of drug with 
albumin were analysed by fitting the data into equation 
described by Vorum et al. (1993). 
53 
A best fit set of Scatchard binding constant was 
obtained by fitting the observed fluorescence quenching 
data to Scatchard's equation: 
j n^ Ck^ 
r = Z 
i=l 1+ Ckji^  
or r = + + + (29) 
1+Ck]^  l+ckj 1+Ckjj 
where r is the molar concentration of bound drug divided by 
the concentration of protein, C is the free drug 
concentration nj^  and kj^  represent the number of binding 
sites and the corresponding binding constant (Scatchard 
constant) in the ith binding class and j is the number of 
binding class. Th r and C were calculated by using equation 
15-19. 
The f i t t ing was then repeated to generate various (30) 
s e t s of acceptable binding cons tan t s . Furthermore, the 
binding observations were also analysed in the terms of 
s to ich iomet r ic assoc ia t ion constant (Adair ' s constant) 
according to Adair's equaiton (Adair, 1925). 
CJCi + 2 C l\-*Ko'"3C K - i K o K o j . . . . . "TNC X\il\o*^'aKM 
r = (30) 
x + C K i + C K I K T ' C K-jKpK-5+ . . . . + 0 K i K o K o K M 
Where kj^  is the stoichiometric association constant for 
step i and N is the maximal value of r, when C W T 
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The s t o i c h i o m e t r i c b ind ing c o n s t a n t , Kj^  ( A d a i r ' s 
constant) can be expressed by Scatchard 's constant , kj^. 
Ki = X k i (31) 
K2 = Z. J i^^ -i 
1 < 3 (32) 
Kl 
'^l'^2 ^N 
% = (33) 
^1^2 ^n-1 
The Adair equation describe any multiple binding 
mechanism including cooperative binding while Scatchard 
equation fails in the presence of cooperativity. 
The sum of weighted (w(cj) and sqaured deviation, S 
was found for the best fit obtained with either equation and 
were compared. 
The S and W (cj) were computed by: 
N [rj - rj (Cj)]2 
S = (Z — r^^ (34) 
j=l W(Cj) 
N - M 
where N is the number of observation and M is the maximum 
number of drug molecules bound, w(c^) is the weighting 
parameter calculated as 
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W(C^) = ( i ^ )2 (35) 
•^  2 
CO is the concentration of free ligand, approximately in the 
middle of a low variation area and q^^ and q2 are parameters 
chosen to allow fair distribution of weighted residuals in 
the observed concentration range. 
Earlier the Adair equation is fitted to the 
experimental data by varying K values to minimize the sum, 
were represented by a set of K value, for best fit 
approximation, performed by the iternative procedure of 
Brodersen et al. (1987) as: 
^i(O) == ^i(best)^ ^° ^^ ^^  
where Z is the normal distributed variate with zero mean and 
a given variance, s^. Z is automatically given a new 
value for each K. 
A probability limit of 0.75 was chosen and a 
corresponding F value is taken from a table of F 
distribution, with equal degree of freedom. The best fit 
was generated repeatedly unitl the S value has decreased to 
an acceptable value, S^^^, fulfiling the condition: 
(Sacc/So) <F (37) 
where so is the value of S in best fit. 
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12. Influence of temperature on drug-albuain interaction: 
The interaction of various drugs with HSA was studied 
at different temperatures, namely 22°, 28°, 34° and 40°C in 
55 mM sodium phosphate buffer, pH 7.0, I 0.11. The 
temperature dependence of association constant was used to 
compute various thermodynamic parameters. These data 
were treated according to van^t Hoff equation. The slope 
of van^t Hoff plot yielded the change in enthalpy ,AH°: 
AH° = - Slope X R (38) 
where R is the gas constant (R= 1.98x10"'' Kcal/mole) 
The change in free energy ( A G ° ) was computed at each 
temperature value by using the following relationship: 
AG° = -RT InKa (39) 
The entropy change (A S°) of the interaction process was 
calculated by: 
A S° = AH° - A G ° / T (40) 
13. Ionic strength dependence of drug-albiain interaction: 
The interaction of these drugs with HSA was studied at 
28°C, pH 7.0 by using 5 mM sodium phoshpate buffer, I 0.01. 
Other ionic strength values, namely 0.05, 0.1, 0.03 and 1.0 
were obtained by including requisite amounts of sodium 
chloride in the buffer. 
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14. Effect of pH on druy-albuBin interaction: 
The drug albumin interaction was studied in pH range 
2.8-10.0 at 28°C, and I O.ll. The various buffer systems 
used, were: 0.06M Tris glycine buffer, pH 2.8, 0.12M Sodium 
acetate buffer, pH 4.0, 0.12 Sodium acetate buffer, pH 4.8, 
0.12 M Sodium acetate buffer, pH 5.5, 0.07 M Sodium 
phosphate buffer, pH 6.5, 0.055M, Sodium phosphate buffer, 
pH 8.0, 0.06M Tris-Hcl buffer, pH 8.5, O.IM Carbonate-
bicarbonate buffer, pH 9.3 and 0.07M Carbonate-bicarbonate 
buffer pH 10.0. 
These interaction studies under different conditions 
of temperature, ionic strength and pH were performed by 
using fluorescence quench titration method. The protein 
concentration was *^  10 uM. 
15. Effect of i^ on protein conforaation: 
The effect of pH on protein conformation was followed 
by measuring fluorescence emission maxima of HSA at 28°C, I 
0.11 using an excitation wavelength of 284 nm. The various 
buffers used were same as described above. 
16. Cheaical Modification of huaan serua albumin: 
Carbamylation of human serum albumin was performed 
by the procedure of stark (1972) using potassium cyanate 
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as the modifying reagent. The different extents 
carbamylation were obtained by varying the reaction time 
instead of increasing concentration of reagent over protein. 
In order to get the desired extent of modification the 
experimental conditions of carbamylation were carefully 
worked out as follows: 
(a) Standarization for Carbamylation: 
Carbamylation was performed at 0.5M concentration of 
potassium cyanate in protein solution, using conventional 
method of Stark (1972). The protein solution containing 
modifying reagent in O.IM sodium phosphate buffer, pH 7.7 
was divided into seven portions. For the six portions the 
carbamylation was allowed to take place as such for 2hr, 
4hr, 8hr, 24hr, 48hr and 96hr respectively. The reaction in 
the seventh portion was performed for 96 hours in the 
presence of 6 M guanidine hydrochloride. The reaction was 
stopped after appropriate times by dialysing the contents 
extensively in 0.1 M sodium phosphate buffer, pH 7.0. The 
extent of modification was determined by the ninhydrin 
method according to Moore and Stein (1954). Extent of 
modification was plotted against reaction time to obtain a 
relation between the time course and degree of modification, 
(b) Conventional Modification 
About 25%, 50% and 80% carbamylated derivatives of HSA 
were prepared at 0.5M concentration of modifying agent by 
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varying reaction time namely 2hr, 6hr, and 96hr respectively 
using a conventional modification technique of Stark (1972). 
Another 100% carbamylated derivative was prepared in the 
presence of 6M guanidine hydrochloride using reaction time 
as 96 hr under same set of conditions as discussed earlier. 
(c) Double Bodification : 
A different approach was used to obtain a carbamylated 
form of HSA, having modification on buried lysine residues 
of protein. This preparation was obtained by double 
modification technique (Mir et al., 1992). This procedure 
involved two successive modification. First, 80% 
citraconylated HSA was prepared (Mir et al., 1992) using 200 
molar excess of citraconic anhydride over protein. For the 
second modification, this 80% citraconylated preparation 
was immediately subjected to carbamylation as described 
above to carbamylate the remaining 20% amino groups. This 
carbamylation was performed in the presence of 6M guanidine 
hydrochloride and the reaction was allowed for a period of 
96 hrs at room temperature. Finally, the citraconyl groups 
were removecV by exposing the protein to 50 mM sodium acetate 
buffer, pH 3.5, for 96 hours at 4 C. At pH 3.5, citraconyl 
group are highly labile (Atassi and Habeeb, 1972) whereas 
the carbamyl groups are completely stable. After this 
process of decitraconylation the protein was dialysed 
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against 0.1 M sodium phosphate buffer, pH 7.0. 
17 Quantification of aodification : 
The number of amino groups ( and ) modified per 
molecule of protein were quantified either by treatment 
with trinitro benzene sulphonic acid (TNBS) as described by 
Habeeb (1966) and/or by ninhydrin method (Moore and Setin, 
1954) 
(a) Reaction with TNBS : 
To 1.0 ml of protein solution (native or modified HSA) 
1 ml of TNBS solution, containing 0.1% (V/V) TNBS in water 
was added. The mixture was incubated at 40*C for 2 hours. 
Then 1.0 ml of 10% (W/V) sodium dodecyl sulphate (SDS) 
solution was added, followed by 0.5 ml of 1 N hydrochloric 
acid. The color intensity was recorded after 10 minutes at 
335 nm against a blank, treated in the same way except that 
it contained 1.0 ml water instead of protein solution. 
The extent of modification was calculated from the 
straight line plots between amount of protein (in mg) and 
absorbance at values for the unmodified and modified HSA 
preparations by using the following equation : 
m 
% modification = 100 ( 1 - ) (41) 
mn 
where m and m^ represent slopes of straight lines obtained 
for modified unmodified HSA respectively. 
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(b) Ninhydrin reaction : 
(i) Preparation of ninhydrin reagent : 
300 mg of ninhydrin and 100 mg of hydrindantin were 
dissolved in 76 ml methylcellusolve and the volume was made 
upto 100 ml with 4M sodium acetate buffer, pH 5.5. This 
o 
reagent was stored in an amber colored bottle at 4 C. 
(ii) Procedure : 
Different amounts of protein (O.l - 1.0 ml) were taken 
in a series of tubes and the final volume was made upto 1.0 
ml with water. One ml of 4 M sodium acetate buffer, pH 5.5 
and 1 ml of ninhydrin reagent were added to each tube. The 
tubes were placed in a boiling water bath for exactly 20 
minutes. After that the tubes were cooled under tap water 
and the contents were diluted with 5 ml of 50% ethanol 
(Ansari et al., 1975). The contents were filtered and the 
color intensity was read at 570 nm against an appropriate 
blank. Absorbance values at 570 nm were plotted against 
protein concentration and the data were analysed by least 
squares method. The extent of modification was determined by 
the same procedure as described earlier with TNBS method. 
18. Interaction of bilirubin with native and modified HSA's : 
The interaction of bilirubin with native and modified 
derivatives of hiiman serum albumin was studied in O.IM Tris 
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- Hcl buffer, pH 8.0, I 0.115 at 28 C by using fluorescence 
quench titration method (Levine, 1977). The method is 
essentially the same as described in detail for studying 
drug -albumin interaction. The preparation of bilirubin 
solution requires extra precaution and was done as follows. 
Stock bilirubin solution was prepared by dissolving 
4 mg of bilirubin in 5 ml IM sodium carbonate solution 
containing 1 mM EDTA. The final volume was made upto 25 ml 
with 0.1 M Tris - Hcl buffer pH 8.0, I 0.11. The solution 
0 . . . 
was filtered and stored xn dark at 4 C. The bilirubin 
concentraction was determined by using a molar absorption 
coefficient of 47500 at 440 nm (Jacobsen and Wennberg, 
1974). All working bilirubin solutions were used the same 
day they were prepared. 
19. Drug induced bilirubin displaceBent : 
The displacement of bilirubin by the three drugs used 
earlier in this cannot be studied by fluorescence quenching 
since these drugs as well as bilirubin produce quenching of 
protein fluorescence upon binding. Fortunately, bilirubin 
which is normally nonfluorescent become fluorescent upon 
binding with albumin and this property can be used for 
studying bilirubin displacement, since the displacing drugs 
do not show this property. The bilirubin -albumin complex 
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gives as emission maximum at 528 nm upon excitation at 487 
nm. Thus, if a drug causes bilirubin displacement then the 
fluorescence intensity at 528 nm would decrease 
proportionally. 
The displacement of bilirubin by indomethacin, 
salicylic acid and chlorp'^mazine was studied in 50 mM sodium 
phosphate buffer, pH 8.0, I 0.15 at 28®C by this method. 
(i) Procedure : 
The fluorescence titration was performed by taking a 
constant amount of protein ( 5 uM) in a series of test tubes 
and adding increasing amounts (0-25 uM) of bilirubin to 
obtain different molar ratio of bilirubin in 0-5 range. The 
final volume was adjusted in each case by the addition of 50 
mM sodium phosphate buffer, pH 8.0, I 0.15. The fluorescence 
emission measurements were made in emission range of 500 -
600 nm by using an excitation wavelength of 487 nm. In 
brief, the various operative conditions of fluorometer 
were: 
Emission range = 500 - 600 nm 
Exciation Wavelength = 487 nm 
Ordinate scale = X 128 
Abscissa scale = X 2 
Slit (excitation) = 5 nm 
Slit (emission) = 5nm 
64 
Sensitivity = High 
Scan speed = Very fast 
The displacement of bilirubin was studied including 
concentration (20 - 100 uM) of each drug in the reaction 
mixture. 
(ii) Analysis of enhancement data : 
The minor modification were made in the method of 
Levine (1977) for analysing these enhancement data. The 
fluorescence intensity at each bilirubin / albuimin molar 
ratio was corrected by subtracting the fluorescence 
intensity of each molar ratio from the fluorescence value at 
zero bilirubin concentration at emission maxima of 528 nm. 
Then, fluorescence intensity was plotted against molar ratio 
of bilirubin over albumin. The inital linear points were 
fitted in a straight line equation with the help of least 
squares analysis. The modified version of equation (14) 
provided the value of e^, (maximal enhancement at bilirubin 
/ albumin molar ratio 1.0). 
ei = Fi - FQ (42) 
Where F^ was the fluorescence at molar ratio 1.0 and FQ was 
the fluorescence at zero bilirubin concentration for each 
fluorescence value F, the faractional enchancement, E was 
calculated by following equation : 
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F - FQ F - FQ 
E = = (43) 
^1 Fl - FQ 
Since, enhancement was linearly related to the extent of 
binding. 
[Bil - Alb] 
E = (44) 
[Alb],j, 
Where [Bil - Alb] was the concentration of bilirubin bound 
albumin and [Alb],j, was the total concentration of protein. 
Finally the unbound and bound bilirubin, albumin 
amounts were determined by using the simple modified version 
of equations 17 - 25. The final form was as follows : 
E 
Ka = (45) 
[1-E] (R - E] [Alb],p 
The transformation of above equation into Scatchard equation 
gave a following relationship : 
E E 
nKa - KaE = = (46) 
[Bil] [R-E] [Alb]rp 
The value of association constant, Ka was obtained from a 
plot between E and E/[Bil] which was analysed by the method 
of least squares. With such a plot, the X intercept gave the 
capacity (n) while the slope gave the value of association 
constant (-Ka). 
RESULTS 
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Preparation of human senim albumin monomer : Human serum 
almbumin monomer was separated from other aggregated forms 
by comumn chromatography on Sephacryl S-200 HR column of 
commercial (sigma) albumin preparation. A typical elution 
profile of commercial HSA preparation is shown in Fig. 5A. 
Three distinct peaks namely T (for tetrameric form), D (for 
dimeric form) and M (for monomeric form) having Vg/V^ 
ratios of 1.06, 1.14 and 1.36 were obtaiend. The fractions 
of peak M indicated by a solid bar under this peak were 
pooled together, concentrated and stored in 60 mM sodium 
phosphate buffer, pH 7.0, I 0.15 at 4''C in the presence of 
0.2% sodium azide. The purity of this preparation was 
checked by gel filtration on Sephacryl S-200 HR column and 
by polyacrylamide gel electrophoresis at pH 8.2. The 
rechromatographic profile of HSA monomer is shown in Fig. 
5B. The electrophoretic patterns of comercial and monomeric 
preparation are shown in the inset of Fig. 5A and B. These 
results indicate that monomeric albumin preparation was 
homogeneous with respect to size and charge. This monomeric 
preparation was used throughout and will be teirmed as HSA 
henceforth. 
Spectral properties of ligands: The uv spectra of various 
drugs namely indomethacin (an anti- inflamatory drug), 
salicylic acid ( an analgesic agent) and chlorpromazine (an 
antipsychotic drug) in wavelenth range of 360-240 nm are 
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Fig. 5. Elution profiles of commercial HSA (A) and HSA 
monomer (B) prepared from commercial HSA on 
sephacryl S-200 HR column (100.5 x 2.4 cm). The 
column was equilibrated with 60 mM sodium 
phosphate buffer, pH 7.0, I 0.15 containing 0.02% 
sodium azide. Five hundred mg of protein 
(commercial HSA) was applied on column. The flow 
rate was 25 ml/hr and 5 ml fractions were 
collected. The fractions were monitored by the 
method of Lowry et al. (1951). Insets (lA and IB) 
show PAGE pattern of commercial and monomeric form 
of HSA. 
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shown in Fig. 6. Inset shows the fluorescence emission 
spectrum of these drugs obtained by using the excitation 
wavelength as 320 nm, 305 nm and 295 nm for indomethacin, 
chlorpromazine and salicylic acid respectively. The values 
of emission maxima ( A max) obtained by uv and fluorescence 
spectroscopy are depicted in Table IV. 
Drug - albumin interaction: The interaction of various drugs 
to human serum albumin was studied by fluorescence quench 
titration method, as earlier used by a number of researchers 
to study the bilirubin-albumin interaction (Levine, 1977; 
Berde et al., 1979; 1984; Tayyab and Qasim, 1989; Mir et 
al., 1992; and Minchiotti et al., 1993). Figure 7 shows 
flurorescence emission spectra of HSA at different 
concentrations of indomethacin, salicylic acid and 
chlorpromiazine. Addition of these durgs causes quenching 
in the fluorescence of HSA. As can be seen that the 
contribution of drug fluorescence emission at wavelength of 
protein flurorescence, emission maximum is negligible. 
Thus usually no corrections are needed and the protein 
fluorescence quenching can directly be related to the extent 
of drug binding. The derivation relating binding constant 
to protein and drug concentration is based on this simple 
assumption. The determination of equilibrium binding 
constant is then reduced to careful measurements of 
fluorescence at different concentration of the drug and 
fitting the data into equations described in the 
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Pig. 6. Ultraviolet absorption spectra of indomethacin 
(tZl salicylic acid (o^) and chlorpromazine 
r>n n°T n'-'?^'^  ^ " ^^ "^ ^'>^^^^ phosphate buffer, 
; L ;T ^^ ^^ ^^ ^ temperature. Instet shows 
the fluorescence emission spectra of indomethacin 
), salicylic acid ( ) and chlorpromazine 
n i T /^oo ^^ sodium phosphate buffer, pH 7.0, 
u.ii at 28 C. The excitaion wavelength values of 
320 nm, 295 nm and 305 nm respectively were used 
tor emission spectral measurements. The druq 
concentration was 10 pg/ml. ^ 
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TABLE - IV 
ULTRAVIOLET AND FLUORESCENCE SPECTRAL FEATURES OF VARIOUS DRUGS IN 
SODIUM PHOSPHATE BUFFER. pH 7.0, I 0.11 AT 301.15K 
Drug Ultraviolet Fluorescence (emission) 
Peak wavelenth fnml Peak wavelength* (nin) 
^ ^ 1 ^ 2 
Indomethacin 320 265 413 
Salicylic acid 295 - 406 
Chlorpromazine 305 250 451 
* at a corresponding value of X^ as an excitation 
wavelength. 
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Fig. 7. Emission spectrum of HSA in absence (upper most 
curve) and in presence of different concentrations 
of indomethacin (A), salicylic acid (B) and 
chlorpromazine iC), (following curves) obtained at 
55 mM sodium phosphate buffer, pH 7.0, I 0.11 and 
28° C. The molar ratios of drug to albumin are 
given in each section. The excitation wavelengths 
were 284 nm (A,C) and 275 nm (B). The dotted 
lines represent the emission spectrum of drugs at 
about 50-55 pM drug concentration. The protein 
concentration was 10.1 pM. 
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experimental section. In order to get an insight into the 
molecular basis of drug- HSA interactions, these 
interactions were studied at different temperatures, pH, 
and ionic strengths. 
Indomethacin-HSA interaction: 
(a) Effect of temperature : The interaction was studied at 
22" c, 28*, 34 C and 40 C in 55 mM sodium phosphate buffer pH 
7.0, I 0.11. Various temperature dependent isotherms are 
shown in Fig. 8. The Scatchard analysis of these data made 
by using equations 12-28, is shown in Fig. 9A. The values 
of association constants, Ka, thus obtained are summarized 
in Table V. The increase in temperature shows a decrease in 
Ka. The data were treated according to the vant Hoff 
equation. The vant Hoff plot is shown in Fig. 9B. The 
value of AH was computed from the slope of vant Hoff plot 
by using equation 38. The other thermodynamic parameters, 
namely AG andAS were obtained with the help of equation 
39 and 40 respectively. The values of AG** ,As and A H° are 
tabulated in Table VI. 
(b) Effect of ionic strength: The effet of ionic strength on 
indomethacin-HSA interaction was studied at 28 C using 5.5 
mM sodium phosphate buffer of pH 7.0. The various ionic 
strengths ( 0.05, 0.10, 0.3 and 1.0 ) were obtained by 
including requistie amounts of sodium chlroide in buffer 
(5.5 mM sodium phosphate, pH 7.0, I 0.011). The 
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Fig. 8. Indomethacin-HSA interaction isotherms obtained in 
55 mM sodium phosphate buffer, pH 7.0, 
The various temperatures used for 
studies were : 22° C (•—•), 28' 
(«—*) and 40" C (A-A) . 
I 0.11. 
interaction 
C (o-o), 34° c 
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Fig. 9(A). Scatchard plots for the interaction 
cin with HSA at pH 7.0, I 0.11 and 
temperatures (22° C, 28° C, 34° C, 
The plots were obtained from the data of Fig.8 
by using equations (12-28). Various symbols are 
the same as described in legend to Fig. 8. 
(B), van't Hoff plot for 
indomethacin with HSA. 
the interaction of 
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TABLE - V 
ASSOCIATION CONSTANT* VALUES OF INDC»IETHACIN - HSA INTERACTION AT 
DIFFERENT TEMPERATURES, IONIC STRENGTHS AND pHS 
CONDITIONS 
Temperature (K) 
(pH 7.0, I 0.11) 
295.15 
301.15 
307.15 
313.15 
Ionic Strength 
(pH 7.0, Temp. 301.15k) 
0.01 
0.05 
0.10 
0.11 
0.30 
1.0 
pH 
(1 0.11, Temp. 301.15 K) 
2.8 
4.0 
4.8 
5.5 
6.5 
7.0 
8.0 
9.4 
10.0 
* In each case n < 1.0. 
ASSOCIATION CONSTANT (Ka) 
(Lit/»ole) 
6.115X10^ 
4.164X10^ 
1.681X10^ 
0.821X10^ 
25.234X10^ 
8.494xl0r 
4.449x10^ 
4.164X10^ 
3.179x10^ 
1.476X10^ 
0.188X10^ 
0.664X10^ 
2.489X10^ 
2.613X10^ 
3.351X10^ 
4.164x10^ 
3.567x10^ 
2.029X10^ 
2.164x10^ 
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TABLE - VI 
THERMODYNAMIC PARAMETERS FOR THE INTERACTION OF INDCMIETHACIN WITH 
HSA AT pH 7 . 0 , I 0 . 1 1 
TEMPERATURE A G ° A S " 
(K) (Kcal/mole) (cal/nole.degree) 
295.15 -7.814 -44.656 
301.15 -7.743 -44.002 
307.15 -7.344 -44.443 
313.15 -7.041 -44.557 
A H " = -20.99 Kcal/mole 
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indomethacin- HSA interaction isotherms, obtained at 
different ionic strength values are shown in Fig. 10.The 
Scatchard plots were obtained with the help of equations 12-
28, are shown in Fig. IIA. THe Ka values are summarized in 
Table V. The plot of ionic strength and Ka is shown in 
Fig. IIB. A steep decrease in association constant with 
increase in ionic strength was observed between ionic 
strength O.Oll to 0.10. Above ionic strength 0.10, the 
decrease in Ka is small. This ionic strength dependency of 
indomethacin - HSA interaction is similar to ionic strength 
dependence of bilirubin-HSA interaction (Jacobsen, 1977). 
(c) Effect of pH: The interaction of indomethacin with HSA 
was studied in the pH range 2.8-10.0 and at constant 
temperature (28 C) and ionic strength ( I 0.11). The binding 
isotherms are shown in Fig. 12 and the Scatchard plots in 
Fig. 13A. The Ka values are depicted in Table V and the 
plot between Ka and pH is shownh in Fig. 13B. The strong 
dependence of Ka on pH below 6.0 is interesting since 
albumin undergoes wellknown Nx-^F transition between pH 5.0 
and 3.0. The N ^—7 F transition in HSA, monitored by 
fluorescence technique is also shown in Fig. 13B. and can be 
seen to be almost superimposable on the Ka dependence on 
pH. The decrease in Ka above pH 8.0 was much smaller and 
probably could be related to the N ^ —7 B conformational 
transition in HSA (Peters, 1985; Carter and Ho, 1994). It 
may also be pointed out M^gi^ 1li^ (9i4lgt]^ BtQmi from pH 6.0 to 3.0 
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Fig. 10 . Indomethacin-HSA interaction isotherms obtained 
in 55 iriM sodium phosphate buffer, pH 7.0 and 
28° C. Various isotherms yielded under 
different conditions of ionic strengths were : 
0.01 (9-9). 0.05 (O—O) , 0.10 (0—0), 0.30 (Q-D) 
and 1. 0 (•-•) . 
K a X 1 0 " ^ ( l i t / m o l e ) 
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Fig. 12. Indomethacin-HSA interaction isotherms obtained 
at 28° C and 10.11. Various isotherms obtained 
under different pH values were : pH 2.8 (ilrr4) , 
4.0 (©-«), 4.8 (H—Q), 5.5 (•—•), 6.5 (O—G) , 
8.0 (D-D), 9.4 (O-O) , and 10.0 (»-•). Various 
buffer systems are given in experimental 
section. 
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will also result in the protonation of the sole carboxyl 
group of indomethacin and may be responsible for the pH 
dependence of Ka in this region. The data points on the pH 
depends of Ka fit nicely into a titration curve and give a 
pK of ^ 4.6, which is very close to the expected pK of 
carboxyl group of indomethacin. 
It can be seen that the value of association constant 
(4.16x10^ M~^) at 28°C pH 7.0 and I 0.11 (See Table V) 
obtained here compares well with the association constant 
values (2.5x10^ to 1.5x10^ M"^) obtained by equilibrium 
dialysis, ultrafiltration and other methods (Mason and Mc-
Queen, 1974; Ekman et al., 1980; Honore et al., 1983; Taira 
and Terada, 1985) for indomethacin-HSA interaction. 
Although Scatchard plot is the classical way of treating 
the binding data and has been extensively used in the past, 
there also have been many comprehensive methods of data 
treatment which instead of taking small portion of binding 
isotherm take the whole binding isotherm and fit it into a 
set of binding constants. One such method has recently been 
described by Vorum et al. (1993). We collaborated with him 
for the treatment of some of our data and he was kind 
enough to use computer programs for our data set. 
The Scatchard and Adair plots obtained by computerized 
curve fitting procedure of Vorum et al., (1993) using 
equations 29 and 30 are shown in Fig. 14. Figure 15 shows 
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Fig. 14. Linear plots for indomethacin-HSA interaction, 
obtained in 55 mM sodium phosphate buffer, pH 
7.0, I 0.11 at 22° C, according to Scatchard 
( ) and Adair ( ) equations. The plots were 
obtained from the data of fig. 8 by using 
equations 29,(Scatchard) and 30,(Adair). 
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log c [M] 
Fig. 15- Log plots for indomethacin-HSA interaction in 55 
roM sodium phosphate buffer, pH 7.0, I 0.11 at 
22° C, according to Scatchard ( •) and Adair 
( ) equations. The plots were obtained from 
the data of Fig. 14. 
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the log form these plots. The computed values of Scatchard 
(Scatchard, 1949) and Adair (Adair, 1925) association 
constants are given in Table Vll. The best fit plot was 
obtained by transformation of Scatchard's constants to 
Adair's since the sum of weighted and squared deviations, 
according to the fitting of Adair equation were not 
significantly smaller than of Scatchard. The best fit plot 
with variation is shown tn Fig. 16 Inset in Fig. 16 shows 
the weighted residuals plot against concentration of unbound 
indomethacin .It can be seen from Table VII that the value 
of primary association constant from Scatchard plot and 
from Adair plot is nearly the same . Further, the good fit 
of the binding data with both Scatchard and Adair equations 
suggests non cooperativity of binding. 
It is clear from the presentation of the binding curve 
in Fig. 14 that the curve is incomplete and some of the 
binding sites were not titrated. In order to get a more 
complete information about possibly all the binding sites of 
indomethacin on HSA, the binding data were obtained up to 
an r value of 5.0. The best fit Scatchard plot for this 
isotherm is shown in Fig. 17. The log plot of this best 
fit is shown in the inset of Fig. 17. The transformed Ka 
values of priamry and folowing binding sites are tabulated 
in Table VIII. It can be seen from Table VIII that beside 
a strong high affinity binding sites,there are several other 
weaker sites are available on HSA for indomethacin. This 
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TABLE - VII 
SUMIARY OF BEST FIT AHALYSIS* FOR INDONETHACIN - HSA INTERACTION 
AT 295.I5K, pH 7.0 AND I 0.11 
a. Step 1 : Fitting of Scatchard's equation (equation 29) to the binding data 
Kaj = 482227 M"} (min: 399 , 900, max: 581000) 
Kap = 2106 M"J (min: 368, max: 3728) 
Ka3 = 2106 M"^ (min: 368, max: 3728) 
b. Step 2: Fitting of Adair's equation (equation 30) to the observed points. 
Ka, = 512801.60 M"J (min: 438640, max: 610070) 
Kap = 361.28 M'} (min: ' 1, max: 2231) 
Kag = 195177.27 M"^ (min: 17294, max: 635740) 
c.Step 3: Computation of sum of weighted and squared deviations (equation 34-35) 
d. Step 4: The sum of weighted and squared deviation according to fitting of 
Adair equations are not significantly smaller than fitting of scatchard. 
Therefore cooperativity is absent . Finally the transformed constants 
(equations 31-33) are: 
Kaj = 486440 M"} (rain: 406190, 
4185 M"} (min: ^ 36, 
Ka3 = 1051 M'^ (min: 184, 
Ka2 
max: 
max: 
max: 
583870) 
7364) 
1856) 
* According to Vorum et al. (1993) 
A range of 30 solutions with a probability limit of 0.75 are shown in 
parenthesis. 
87 
log c [M] 
Fig. 16. Best fit plot for indomethacin-HSA interaction, 
obtained in 55 mM sodium phosphate buffer pH 
7.0, I 0.11 at 22° c. Dotted lines show the 
deviation (downwards and upwards) in minimum 
and maximum values with the probability range of 
0.75. Inset shows the weighted residuals plot 
obtained by using the equation 35. 
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Fig. 17. Scatchard plot for the interaction of 
indomethacin with HSA at pH 7.0, I 0.11 at 28°C. 
The plot was obtained from the data of complete 
indomethacin-HSA interaction (see inset: A log 
plot of interaction data according to Scatchard 
equation, 29) by transforming Adair's constants 
to Scatchard constant using equation 33. 
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TABLE - VIII 
A COMPLETE SET OF ASSOCIATION CONSTANTS FOR INDOMETHACIN 
-HSA INTERACTION* OBTAINED BY BEST FIT ANALYSIS 
Kaj^ 
Ka^ ^ 
Ka2 
Ka3 
Ka4 
Kag 
Kag 
Kaj 
* at Temp. 
Nunerical value (lit/iRole) 
4.01X10^ 
1.1X10^ 
5.4X10^ 
6.6X10^ 
519 
236 
0.46 
301.15K pH 7.0, I 0.11 
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contradicts with the ealier report stating that the 
indomethacin binds to three sites with high affinity, having 
association constants as 1.5-2.1 x 10^ M"-*^, 3.5xl0^ M~-'-
and S.Sxlo'* M"-*^  for primary, secondary and tertiary binding 
sites respectively (Ekman et al., 1980). 
since the vaue of primary association constant, 
obtained by best fit procedure (Vorum et al., 1993) were in 
good agreement with that obtained from simple Scatchard 
analysis ( a comparative evaluation is sumroariszed in 
Table IX), the later method has been used to study the 
interaction of other ligands to HSA. 
Salicylic acid-HSA interaction: 
The interaction of salicylic acid with HSA was 
studied under similar set of experimetal conditions as were 
employed for studying the indomethacin- HSA interaction. 
The only differnce in this study with earlier one was that 
the A (excitation) used here was 275 nm to counter the 
effect of drug at >^ max (emission) of HSA. 
(a) Effect of temperature: The effect of temperature on 
salicylic acid-HSA intercation studied at 4 different 
temperature values namely, 22*C, 28*0, 34°C and 40°C. 
Various isotherms, obtained at these different temperature 
marks are shown in Pig. 18. The Scatchard plots were 
obtained with the help of equations 12-28, are shown in Fig. 
19A. The decrease in slope with increase in temperature is 
an indication of decrease in affinity of drug to albumin. 
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TABLE - IX 
ASSOCIATION CONSTANT VALUES OF INDONETHACIN-HSA INTERACTION OBTAINED BY 
BEST FIT ANALYSIS AT DIFFERENT TEMPERATURES, IONIC STRENGTHS AND pHs. 
CONDITIONS 
Kai 
ASSOCIATION CONSTANTS. I^a nit/«o1e) 
Ka^i Ka^  
5 
Temperature (K) 
(ph 7.0, 1 0.11) 
295.15 4.87x10, 
301.15 3.61xl0j 
307.15 2.65x10^ 
313.15 2.48x10^ 
Ionic strength 
(pH 7.0, Temperature 301.15K) 
0 
0, 
0. 
0. 
0. 
01 
05 
10 
11 
30 
1.2x10^ 
4.6x10^, 
3.61x10-
2.7x10^ 
1.0 
pH 
(I O.IL Temp 
2.8 
4 
4 
5 
6 
301.15 K) 
.8x10^ 
,7x10^ 
.9x10^ 
,9x10^, 
61x10-
9x10^ 
10.0 
l!9xl0^ 
1.9x10-
(6.115x10^) 4.19x10: 
(4.164x10^) 4.8 xlO-
(1.681x10^) 3.9 xlO; 
(0.821x10^) 3.6 xlO-
(2.5x10^)-
(8.494x10^) 
(4.449x10^) 
(4.164x10^) 
(3.179x10^) 
(1.476x10^) 
(0.188x10^) 
(6.64xlO^J 
(2.489x10^) 
(2.613x10^) 
(3.351x10=) 
(4.164x10^) 
(3.567x10^) 
(2.029x10^) 
(2.164x10^) 
10x10^ 
3.6x10: 
8x10: 
6x10-
877 
677 
1.5x10^ 
2.0x10:? 
4.8x10^ 
4.3x10^ 
4.3x10^ 
1083 
1.1x10: 
1.2x10-
819 
705 
2.3x10^ 
1.4xI0f 
1.2x10-^  
167 
376 
469 , 
1.2x10^ 
1x10^ 
1x10-^  
272 
The values of association constant, obtained by Scatchard analysis of 
Levine's method (See Table V) are given in parenthesis). 
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Fig. 18. Salicylic acid-HSA interaction isotherms 
obtained in 55 itiM sodium phosphate buffer/ pH, 
7.0 I 0.11. The various temperature values used 
for interaction studies were : 22° C (•—•)» 
28° C (O-O) , 34° C ^—ir) and 40° C (Ar-A) . 
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c 
1/TxlO^ 
Fig.19(A).Scatchard plots for the interaction of salicylic 
acid with HSA at pH 7.0, I 0.11 and at different 
temperature values (22° C, 28° C, 34<=> C and 
40° C). The plots were obtained from the data 
of Fig. 18 by using equations (12-28). Various 
symbols are the same as described in the legend 
to Fig. 18. 
(B).van't Hoff 
interaction. 
plot for salicylic acid-HSA 
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The values of association constants are depicted in Table 
X. The vant Hoff plot, generated from these Ka values is 
shown in Fig. 19 B. Various thermodynamic parameters, as 
givne in Table XI were computed by using equation 38-40. 
The lower value of enthalpy change (^  - 7 Kcal/mole) 
associated with positive value of entropy (<^+2 cal/mole. 
degree) shows a opposite trend from that obtaiend with 
indomethacin - HSA study. 
(b) Effect of ionic strength: Various isotherms of salicylic 
acid-HSA interaction were obtained in ionic strength range 
0.01 to 1.0 are shown in Fig. 20. The Scatchard plots of 
these data are shown in Fig. 21A, and Ka values are given 
in Table X. It can be seen that magnitude of decrease in 
Ka upon increase in ionic strength is smaller as compared 
to indomethacin- HSA interaction. Fig. 21 B. shows t*he 
relationship between Ka and ionic strength. 
(c) Effect of pH: Salicylic acid-HSA interaction isotherms 
obtained in pH range 2.8 to 10.0 are shown in Fig.22.The 
Scatchard plots of these isotherms are shown in Fig. 23A, 
while their corresponding Ka values are depicted in Table X. 
A plot between pH and Ka is shown in Fig. 23B. A decrease 
in association constant can be seen in acidic and basic pH 
range. It is plausible that in pH range 3-6, the 
ionization of only carboxyl group of drug will take place. 
Moreover, the role of conformational change in this region 
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TABLE - X 
ASSOCIATION CONSTANT* VALUES OP SALICYLIC ACID- HSA 
INTERACTION AT DIFFERENT TEMPERATORES, IONIC STRENGTHS AND 
pHs 
CONDITIONS ASSOCIATION CONSTANT, Ka 
(Lit/mole) 
Temperature (K) 
(pH 7.0, I 0.11) 
295.15 
301.15 
307.15 
313.15 
4.175X10-
3.038xl0{ 
2.278X10; 
2.121X10-
Ionic strength 
(pH 7.0, Temp. 
0.01 
0.05 
0.11 
0.15 
0.30 
1.0 
301.15K) 
6.515X10; 
5.185X10; 
3.038X10; 
2.516X10; 
1.018X10; 
0.887X10-
PH 
(I 0, 11, Temp, 
2.8 
4 
4, 
5. 
6. 
7.0 
8.0 
9.4 
10.0 
0 
8 
5 
5 
301.15K) 
o.oiixio; 
0.654X10; 
1.805X10; 
2.294X10; 
2.338x10; 
3.038X10; 
0.887X10; 
0.910x10; 
1.377x10-
* In each case n < 1.0, 
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TABLE - XI 
TERMODYNAMIC PARAMETERS FOR THE INTERACTION OF SALICYLIC 
ACID WITH HSA AT pH 7.0, I 0.11 
TEMPERATURE 
(K) 
295.15 
301.15 
307.15 
313.15 
AG" 
(Kcal/mole) 
-7.590 
-7.555 
-7.529 
-7.632 
As" 
(cal/ntole. degree) 
+2.000 
+1.842 
+1.723 
+2.018 
A H = -6.999 Kcal/mole 
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Fig. 20 . Salicylic acid-HSA interaction isotherms 
obtained in 55 mM sodium phosphate buffer, 
pH 7.0, at 28° C. Various isotherms, yielded 
under different conditions of ionic strengths 
were : 0.01 (©—©), 0.05 (O—O), 0.15 (0—O), 
0.30 (D-O) and 1.0 (•-•). 
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Fig. 22 Salicylic acid-HSA interaction isotherms 
obtained at 28° C and I 0.11. Various 
isotherms obtained under different pH conditions 
were : 2.8 (^-~^), 4.0 {Q—Q), 4.8 (B-H), 5.5 
(#—#), 6.5 (©—©), 8.0 (D—O), 9.4 (O—O), and 
10.0 (••-•). Various buffer systems are given in 
experimental section. 
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(pH 3.0 to 6.0) via NK^F transition (Peters, 1985; carter and 
Ho,1994) may be crucial since the location of aspirin,a 
derivative of salicylic acid is found to be in IIA IIIA 
subdomains (He and Carter,1992). 
CHlorproBazine - HSA interaction: 
The interaction of chlorpromazine to human 
serum albumin was also studied at different temperature, 
ionic strength and pH values. 
(a) Effect of tempeature: Four temperature values namely 
22'^ C, 28 °C, 34^C and 40°C were selected to study the -effect 
of temperature on chlorpromazine-HSA interaction. Various 
isotherms, obtained at these temperature values are shown 
in Fig. 24. The Scatchard plot of these data, obtaiend by 
using equation, 12-28 are shown in Fig. 25A. Values of 
association constants are summarized in Table XII. Figure 
25B. shows the van*t Hoff plot of this study. Various 
thermodynamic parameters, computed with the help of 
equaitons 38-40 are tabulated in Table XIII. A minimum 
value of AH° ( -1.27 Kcal/mole) with a high positive value 
of As** (-19.7 cal/mole. degree) fits well in Kauzmann 
model (Kauzmann, 1959) with the presence of hydrophobic 
interactions in chlorpromazine-HSA interaction. 
(b) Effect of ionic strength: The effect of ionic strength 
on chlorpromazine -HSA interaction was studied in ionic 
strength range of 0.01 to 1.0. Fig. 26 shows the 
chlorpromazine - HSA interaction isotherms, obtained at 
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Pig. 24 . Chlorpromazine-HSA interaction isotherms 
obtained in 55 mM sodium phosphate buffer pH 
7.0, I 0.11. The various temperatures used for 
interaction studies were : 22° C (•—•), 28° C 
(O—O), 34° C i^—i^ and 40° C (A-^) . 
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Fig.25(A), Scatchard plots for the interaction of 
chlorpromazine with HSA at pH 7.0 I 0.11 and at 
different temperatures (22° C, 28° C, 34° C and 
40° C). The plots were obtained from the data 
of Fig. 24 by using equations (12-28). Various 
symbols are the same as described in legend to 
Fig. 24. 
(B)^van't Hoff plot for 
* chlorpromazine with HSA. 
the interaction of 
1 0 4 
TABLE - X I I 
ASSOCIATION CONSTANT* VALUES OF CHLORPROMAZINE- HSA 
INTERACTION AT DIFFERENT TEMPERATDRES, IONIC STRENGTHS AND 
pHs 
CONDITIONS ASSOCIATION CONSTANT, Ka 
(Lit/iBole) 
Temperature (K) 
(pH 7.0, I 0.11) 
295.15 
301.15 
307.15 
313.15 
1.721x10-
1.684X10J 
1.619X10; 
1.50 XlO-
lonic strength 
(pH 7.0, Temp. 301.15K) 
0.01 
0, 
0. 
0. 
0. 
05 
10 
11 
30 
1.0 
1.212x10; 
1.382X10; 
1.505x10; 
1.684x10; 
1.768x10; 
1.802x10-
PH 
(I 0.11, Temp. 
2 
4 
4 
5 
6 
7 
8 
9 
,8 
,0 
,8 
,5 
,5 
,0 
0 
4 
301.15K) 
0.706x10-
10.0 
336X10; 
509X10; 
520x10; 
522X10; 
684x10; 
3.099x10; 
18.822x10; 
36.244x10-
* In each case n < 1.0, 
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TABLE - XIII 
TERNODYNAMIC PARAMETERS FOR THE INTERACTION OF 
CHLORPRQMAZINE WITH HSA AT pH 7.0, I 0.11 
TEMPERATURE A G A s" 
(K) (Kcal/Bole) (Cal/Bole.degree) 
295.15 -7.071 +19.664 
301.15 -7.201 +19.705 
307.15 -7.321 +19.709 
313.15 -7.416 +19.637 
A H " =-1.267 Kcal/mole 
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Fig. 26. Chlorpromazine-HSA interaction isotherms 
obtained in 55 mM sodium phosphate buffer, pH 
7.0/ at 28° C. Various isotherms/ yielded under 
different conditions of ionic strengths were : 
0.01 (©—©), 0.05 (O-O), 0.10 (O—O), 0.30 (D—Q) 
and 1.0 (•-•). 
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different ionic strength values. Scatchard plots of this 
study are shown in Fig. 27A and Ka values are depicted in 
Table XII. The plot between ionic strength and Ka is shown 
in Fig. 27B. It can be seen that an increase in ionic 
strength leads to an increase in Ka. It holds true with the 
outcome of temperature based study that hydrophobic 
interaction are of prime importance in this interaction. 
(c) Effect of pH: A pH range of 2.8 to 10.0 was used to 
study the chlorpromazine-HSA interaction. Various isotherms 
obtained at different pH values are shown in Fig. 28. The 
Scatchard plots of these pH dependent iostherms are shown 
in Fig. 29A. The value of association constants are 
tabulated in table XII. An insignificant change in Ka in pH 
range 4-6.5 (N^ r^ F transition range) can be seen from a plot 
between pH and Ka (Fig. 29B). A dramatic increase in Ka upon 
increase in pH beyond 7.0 ( in Hx^B transition) is similar 
to that of warfarin and diazepam - HSA interaction (Wilting 
et al., 1980a, 1980b) and others (vander Giesen and wilting, 
1982, Dorge et al., 1982, Vorum, 1987, Era et al., 1990, 
Carter and Ho, 1994). 
Cheaical Bodification of HSA: Various carbamylated 
derivatives of HSA differing in their extent of lysine 
modification were prepared using conventional modification 
technique (Stark, 1970, 1972). Potassium cyanate, (KCNO) was 
used as a modifying reagent. Additionally, a protein 
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2 4 
Molar ratio, [Chi /HSA] 
Fig. 28. Chlorpromazine-HSA interaction isotherms 
obtained at 28° C and I 0.11. Various isotherms 
obtained under different pH values were : 2.8 
(^-A), 4.0 (©—©), 4.8 (B—H), 5.5 (#—•), 6.5 
(©—©), 8.0 (D-O), 9.4 (O—O), and 10.0 (•-«). 
Various buffer systems are given in experimental 
section. 
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derivative having modified buried lysine residue(s) was 
prepared using double modification technique (Mir et al., 
1992). Earlier results based on modification of BSA have 
indicated exposure of^80% lysine residues in native protein 
(Jonas and Weber, 1970; Tayyab and Qasim 1986). Therefore, 
the carbamylation of remaining (-.^ 20%) lysine residues was 
achieved according to dobule modificaion technique (Mir et 
al., 1992), as discussed in experimental section. 
Experimental conditions, to get a desired modification 
were worked out as described earlier in experimental 
section. In this regard, a pilot experiment was performed in 
the presence of 0.5 M KCNO over protein concentration in 
O.IM sodium phosphate buffer, ph 7.7 at room temperature by 
varying reaction time (2-96 hr). In Addition to this a 
maximally carbamylated preparation of HSA was ensured, 
keeping the reaction mixture (protein + KCNO) for 96 hrs in 
the presence of 6M Gdn Hcl under similar experimental 
conditions as stated earlier. The extent of modification was 
measured either by ninhydrin and/or TNBS method using 
equation 41. The outcome fo pilot experiment, based on 
ninhydrin method is shown in Fig. 30. Inset shows the 
relationship between reaction time and percent modification 
of lysine residues. It can be seen from inset that three 
type of lysine residues are present on HSA molecule namely, 
fast reacting (exposed), slow reacting (partially exposed) 
and unreacting, even at a higher reaction time (presumably 
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Fig. 30. 
Plots of ninhydrin color intensity versus 
protein concentration for native and different 
carbamylated HSA preparations. Albumin 
preparations are : Native HSA (•—•), HSA treated 
with 0.5 M KCNO for varying time intervals : 2 
hrs (O—O), 4 hrs (it—A), 8 hrs (D-D)/ 12 hrs 
(A—A), 48 hrs (H—H)/ and 96 hrs (^—>e). A 
carbamylated preparation, treated in the 
presence of 6M Gdn Hcl for 96 hrs is shown by 
0—0. Straight lines were drawn by the method 
of least squares. Percent modification was 
calculated by equation 41 is shown in 
parenthesis. Inset shows a correlation between 
percent modification and reaction time. 
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buried). It fits well with earlier finding of Tayyab and 
Qasim (1986). 
The strategy, based on the outcome of pilot experiment 
to modify the HSA is summerized in Table XIV. The 
determination of extent of modification was made by 
ninhydrin and TNBS method is shown in Fig. 31. These results 
are summerized in Table XIV. The various modifications, 
thus obtained were: 23%, 55%, 77%. 98% and (21%), having 
modification at buried lysine residues. 
Homogeneity of carbamylated derivatives: The homogeneity of 
various albumin derivatives was established by PAGE at pH 
8.2 and by column chromatography on a sephacryl S-200 HR 
column. 
(a) Polyacrylamide gel electrophoresis: The electrophoresis 
was performed at pH 8.2 in Tris (4.95mM)-glycine (38mM) 
buffer. All the modified albumin preparation gave a single 
protein bands indicating homogeneity with respect to extent 
of modification . The electrophoretic patterns are shown in 
Fig. 32. The relative mobility of different albumin 
preparation was computed using equation 11 is mentioned in 
Fig. 32. Carbamylation leads to neutralization positive 
charge of lysine residues. Thus, the increased net negative 
charge of carbamylated preparations explains their higher 
relative mobility as compared to native HSA. In case of two 
highly carbamylated preparations namely 77% and 98% Cbl-HSA 
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REAGENT 
Potassium 
Cyanate 
{0.5M) 
TABLE - XIV 
CHEMICAL MODIFICATION OF HUNAN SERUM ALBUMIN 
REACTION CONDITIONS 
t a. 2 Mrs, RT, pH 7.7 
b. 6 Hrs, RT, pH 7.7 
c. 96 Hrs, RT, pH 7.7 
d. 96 Hrs, in presence 
of 6 M Gdn Hcl, RT, 
pH 7.7 
e** 96 Hrs in presence < 
6M Gdn Hcl., RT 
pH 7.7 
X MODIFICATION 
NINHYDRIN 
METHOD 
24 
55 
78 
99 
3f 21 
TNBS MEAN 
METHOD 
22 23 
55 55 
76 77 
97 98 
21 (21)' 
NO OF AMINO 
GROUPS MODIFIED* 
•** 
14 
33 
46 
59 
14 
** 
*** 
The number of amino groups modified was calculated by taking the 
total number of amino groups to be 60 [one "^ and 59 lysine 
residues (Peters, 1985). 
80% citraconylated HSA was prepared by the method of Butler and 
Hartley (1972). Finally,the KCNO treated HSA was subjected to 
decitraconylation (Atassi and Habeeb, 1972) at pH 3.5. 
Preparation has buried lysine residues modified. 
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Amount of protein (mg) 
Fig. 31. Plots for the determination of extent of 
modification by TNBS method (A) and ninhydrin 
method (B) for native HSA and its carbamylated 
forms. The various albumin preparations are 
represented as : native HSA (N), 23% Cbl-HSA(l), 
55% Cbl-HSA (2), 77% Cbl-HSA (3), 98% 
Cbl-HSA(4), and (21%) Cbl-HSA(5). 
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N A B C D E 
(0.44) (0.44) ^ ^ (Q^^j 
-*' (0.83)(0.86)(0.72) 
Fig. 32 Polyacrylamide gel electrophoretic patterns of 
native HSA (N) , 23% Cbl-HSA (A), 55% Cbl-HSA 
(B), 77% Cbl-HSA (C), 98% Cbl-HSA (D) and (21%) 
Cbl-HSA (E) on 10% gel at pH 8.2 (4.95 mM 
tris-38 mM glycine buffer, pH 8.2). The 
electrophoresis was carried out by applying a 
current of 1.5 itiA per well. The gel was 
strained with 0.1% conunassie blue R-250 in 42% 
(v/v) methd^ nol and 17% (v/v) acetic acid and 
destained in 7% acetic acid. The position of 
tracking dye is show by an arrow. The r values 
obtained by equation 11 given in parenthesis. 
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the relative mobility was not as high as expected. This is 
probably due to the fact that these preparations of HSA 
undergo an increase in stokers radii which will have a 
tendency to decrease its relative mobility. The 23% Cbl-
HSA and (21%) Cbl - HSa shows an identical vlaue of 
relative mobility as compared to HSA. 
(b) Column chromatography: The elution profiles of native 
and modified HSA preparations are shown in Fig. 33. As can 
be seen each preparation eluted with a single symmetrical 
peak indicating size homogeneity in each albumin 
preparation. 
Hydrodynamic properties: 
(a) Determination of Stokes radius: The hydrodynamic 
properties of HSA and its modified derivatives such as 
stokes radius and frictional ratio were studied by gel 
chromatography on a calibrated sephacryl, S-200 HR column 
at pH 7.0, I 0.15. The column was calibrated by passing 
standard proteins of known hydrodynamic properties (see 
Table XV). The void volume and inner volume were determined 
by passing blue dextran-2000 and potassium ferricyanide 
through the column. The elution profiles of marker protein 
are shown in fig. 34. All the modified derivatives of HSA 
eluted as single symmertical peaks (see Fig. 33) emphasizing 
size homogeneity in these preparations. The elution volume 
for each protein was determined 2-3 times and the error in 
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TABLE - XV 
GEL FILTRATION DATA FOR MARKER PROTEINS AND VARIOUS NODIFIED ALBUMIN 
DERIVATIVES OBTAINED BY CHROMATOGRAPHY ON SEPHACRYL S-200HR COLUMN* 
(62X1.68 CM) IN 60#l SODIUM PHOSPHATE BUFFER, pH 7.0, I 0.15 
PROTEINS Ve(»l) Kd Kav (-log Kav)^/^ erfe'^Kd 
y-Globulin (5.3nm) 57 0.061 0.09 1.023 1.322 
Tyrosinase (4.23 nm) 61 0.092 0.135 0.933 1.188 
Ovalbumin (2.73 nm) 70 0.160 0.236 0.792 0.991 
0.839 
1.047 
1.047 
1.090 
1.136 
1.221 
1.047 
Stokes radii of marker proteins (taken from Andrews (1970) are given 
in parenthesis 
Void volume = 49 ml and inner volume = 131 ml. 
o^-Chymotrypsinogen A 
(2.24 nm) 
Native HSA 
23% Cbl-HSA 
55% Cbl-HSA 
77% Cbl-HSA 
98% Cbl-HSA 
21% Cbl-HSA 
80 
67 
67 
65 
63 
60 
67 
0.237 
0.137 
0.137 
0.122 
0.107 
0.084 
0.137 
0.348 
0.202 
0.202 
0.180 
0.157 
0.124 
0.202 
0.677 
0.833 
0.833 
0.863 
0.896 
0.953 
0.833 
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I 
the determination of elution volume was less than ±0.5 ml. 
The elution voluems of different proteins were normalized 
with the help of equation 6-7. The gel filtration data are 
summarized in Table XV. The data were analysed by the 
equaitons 8 and 9 of Laurent and Killender (1964) and 
Ackers (1967) respectively. The plots of stokes radius 
against (-log Kav)^/^ and erfc"'-'^  Kd are shown in Fig. 35A 
and B. The least squares analysis of the data gave 
following two equations: 
(-log Kav)-"^ /^  = 0.107 r + 0.467 (47) 
erfc~^Kd = 0.150 r + 0.541 (48) 
(b) Determination of frictional ratio : The frictional ratio 
was determined with the help of gel filtration data. 
Frictional ratio (f/fQ) was calculated from stokes radius 
by equation 10. 
The values of stokes radius and frictional ratio are 
given in Table XVI. The increase in stokes radius ( from 
3.39 nm to 4.5 nm) and frictional ratio ( from 1.26 to 
1.68) for unmodified to maximally (98%) carbamylated HSA 
suggests that protein molecule undergoes considerable 
conformational changes (expansion ) upon modification. The 
change in both parameters is more pronounced in two highly 
modified derivatives (i.e 77% Cbl-HSA and 98% Cbl-HSA) but 
remains uneffected upto 23% modificaiton. Thus, these two 
modified preparations, namely, 23% Cbl-HSA ( having 
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TABLE - XVI 
HYDRODYNAMIC PARAMETERS OF HSA AND ITS NQIFIED DERIVATIVES 
Proteins 
Native HSA 
23% CBl-HSA 
55% Cbl-HSA 
77% Cbl-HSA 
98% Cbl-HSA 
(21%) Cbl-HSA 
Stokes radius.rm 
Laurent and 
Killander (1964) 
3.37 
3.37 
3.66 
3.96 
4.53 
3.37 
Ackers 
(1967) 
3.41 
3.41 
3.69 
4.00 
4.53 
3.41 
Mean 
3.39 
3.39 
3.68 
3.98 
4.53 
3.39 
f/^o 
1.26 
1.26 
1.37 
1.48 
1.68 
1.26 
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modification of exposed lysine residues) and (21%) Cbl- HSA 
with modification of buried lysine residues, with 
insignficant/no conformational alteration would be helpful 
in understanding the role/nature of lysine residues in drug 
binding. 
Bilirubin-HSA interaction: Fluorescence quench technique was 
employed to study the interaction of bilirubin with HSA 
and is modified forms at pH 8.0. This technique was found 
to be a well versed to study bilirubin-albumin interaction 
(Levine, 1977, Berde et al., 1979, 1984, Tayyab and Qasim, 
1989, Mir et al., 1992, Minchiotti et al., 1993). Bilirubin 
interaction isotherms of HSA and its modified forms are 
shown in Fig. 36. Increase in chemcial modification 
resulted a decrease in relative fluorescence is an 
indication of decrease in affinity of bilirubin-albumin 
interaction upon modification. The data were analysed for 
determination of association constant by utilizing 
equations 12-28. The Scatchard plots for native and modified 
albumins are shown in Fig. 40A. The values of association 
constant are summerized in Table XVII. The association 
constant of HSA was found to be 3.63x10^ M"^ which is in 
good agreement with earlier reported values (see Table III). 
A significant decrease in Ka can be seen in case of 98% Cbl-
HSA and (21%) Cbl-HSA derivatives. 
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Molar ratio, CBil /AlbJ 
Fig. 36, Interaction isotherms of bilirubin with HSA and 
its carbamylated derivatives obtained in O.lM 
Tris-Hcl buffer, pH 8.0, I 0.115 at 28'> C. 
Various albumin preparations were : Native HSA 
(•-•), 23% Cbl-HSA (©-Q), 55% Cbl-HSA (©—«), 
77% Cbl-HSA (DMa), 98% Cbl-HSA (•—•) and (21%) 
Cbl-HSA (O—O) . 
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Interaction of drugs with carbaMylated HSA derivatives: 
Interaction of various, anionic (indomethacin and salicylic 
acid) and cationic (chlorpromazine) drugs with modified 
o 
derivatives of HSA was studied at pH 7.0, 28 C and I 0.11 
by fluorescence guench technigue. Interaction isotherms of 
indomethacin. salicylic acid and chlorpromazine with native 
and modified derivatives of HSAs are shown in Fig. 37-39. A 
significant effect on relative fluorescence can be seen in 
case of indomethancin and salicylic acid upon extent of 
modification. Interestingly, (21%) Cbl-HSA shows a high 
degree of change in relative fluorescence as compared to 
its counterpart, 23% Cbl-HSA with indomethacin. The changes 
in relative fluorescence upon modification are less in case 
of chlorpromazine interactions. The scatchard plots of 
these interaction were obtained by using eguations 12-28, 
are shown in Figs. 40 B,C and D. The values of association 
constant are summarized in Table XVII. It can be seen from 
table XVII that about 10 fold decrease in Ka of indomethacin 
with maximally modified (98% Cbl-HSA) derivative is somehow 
lesser to that obtained with (21%) Cbl-HSA with a mark of 52 
fold decrease in Ka. Salicylic acid shows a decrease of 
about 50 fold in Ka with 98% Cbl- HSA, while in case of 
(21%) Cbl- HSA its value is only 3 fold. Insiginificant 
decrease in Ka can be seen with chlorpromazine upon chemical 
modification. 
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Fig, 37, Interaction isotherms of indomethacin with HSA 
and its carbamylated derivatives obtained in 55 
itiM sodium phosphate buffer, pH 7.0, I 0.11 at 
28° C. Various albumin preparations are the same 
as described in the legend to Fig. 36. 
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Fig. 38^ Interaction isotherms of salicylic acid with HSA 
and its carbamylated derivatives obtained in 
55 mM sodium phosphate buffer, pH 7.0, I 0.11 at 
28° C. Various symbols are the same as 
described in the legend to Fig. 36. 
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Fig. 39. Interaction isotherms of chlorpromazine with HSA 
and its carbamylated derivatives obtained in 
55 mM sodium phosphate buffer/ pH 7.0, I 0.11 at 
28° C. Various albumin preparations are the 
same as described in the legend to Fig. 36. 
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TABLE - XVII 
ASSOCIATION CONSTANT* VALUES FOR INTERACTION OF VARIOUS LIGANDS HITH 
NATIVE AND MODIFIED DERIVATIVES OF HUNAN SERUM ALBUMIN 
HSA PREPARATION 
Native HSA 
23% Cbl-HSA 
55% Cbl-HSA 
77% Cbl-HSA 
98% Cbl-HSA 
(21%)Cbl-HSA 
ASSOCIATION CONSTANT, fa (1it/«o1e) 
Bilirubin Indonethacin Salicylic acid Chloroaazine 
3.63x10 
2.20x10 
7 
7 
5.68x10^ 
2.23x10^ 
4.77x10^ 
6.87x10^ 
4.16X10^ 
1.99X10* 
1.51x10* 
0.58x10* 
0.45x10* 
0.08x10* 
3.04X10= 
2.85X10^ 
1.74x10^ 
0.76x10^ 
0.06x10^ 
1.04x10^ 
1.68X10= 
1.71X10^ 
1.34x10^ 
1.07x10^ 
0.99x10^ 
1.58x10^ 
* In each case n < 1.0. 
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Drug induced bilirubin displaceaent: A technique of 
'fluorescence enhancement' was employed to study the drug 
induced bilirubin displacement from albumin. In an encounter 
during the study of fluorescence properties of bilirubin-
albumin complex, it was noticed that bilirubin upon 
complexation gives a typical fluorescence. The spectrum 
was characterized with a emission maximum of 528 nm at a 
value of 487 nm of excitation maximum. Increasing 
concentration of bilirubin over albumin caused an increase 
in fluorescence intensity at 528 nm, henceforth reffered as 
"fluorescence enhancement". The model fluorescence, 
enhancement phenomenon is shown in Fig. 41A. The 
contribution of bilirubin is negligible in the wavelength 
range 500- 600 nm where the bilirubin HSA complex emits. 
Addition of drug (bilirubin displacer in nature) leads to 
a decreased enhsmcement of fluorescence at 528 nm. The 
model showing the bilirubin displacement in the presence of 
varying concentration of indomethancin namely 20, 50 and 100 
yM is illustrated in Fig. 41.B—^D. A decrease in 
fluorescence intensity upon addition of drug is mainly 
attributed to the displacement of bilirubin from its complex 
with albumin. 
The incubation time for maximum bilirubin displacement 
by drugs was worked out in the presence of 20uM 
concentration of drug. In this regard, the fluorescence 
intensity values were recorded at a time interval of 0, 
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Fig. 41. Fluorescence emission spectra of bilirubin 
albumin complexes in the absence (A) and the 
presence of different concentrations of 
indomethacin namely, 20.1 uM (B), 50 uM (C) and 
100 uM (D) obtained in 50 mM sodium phosphate 
buffer, pH 8.0, I 0.15 at 28° C. Molar ratios 
of Bil/HSA used (with their spectral positi.on's 
in parenthesis) were : 0(1), 0.05(2), 0.10(3), 
0.15(4), 0.20(5), 0.30(6), 0.40(7), 0.50(8), 
0.60(9), 0.70(10), 0.80(11), 0.90(12), 1.0(13), 
2.5(16), 3.0(17), 4.0(18), and 
shown in each section are 
from top to bottom. The excitation wavelength 
was 487 nm and albumin concentration was 5 pM. 
5(14), 
0(19). 
2.0(15), 
Positions 
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0.5, 2.5, 5, 10, 15, 20, 25 and 30 minutes. The plot of 
incubation time against percent decrease in fluorescence 
intensity is shown in fig. 42. It can be seen that all 
three drugs require about 10 minutes to give maximum 
displacement. 
The bilirubin displacement was studied in the presence 
of 20, 50 and 100 uM concentration of drugs, namely, 
indomethacin, salicylic acid and chlorpromazine at pH 8.0, 
0 . . . . . 
28 C, I 0.15. Various isotherms of bilirubin-albumin 
interaction in the absence and presence of 20,50 and 100 uM 
concentration of drugs are shown in Figs. 43-45 (A). As can 
be seen that bilirubin-albumin complexation in the zero 
concentration of drug shows a decrease in fluorescence 
intensity at higher bilirubin molar ratio ( after 2-3). 
Probably, after saturation of high and low affinity binding 
sites, the excess unbound bilirubin acts as a quencher of 
fluorescence. 
The drug induced decrease in fluorescence intensity at 
528 nm from bilirubin/HSA molar ratio 0-1.0 was taken into 
account to quantify the effect of drug concentrations on 
bilirubin displacement from its primary binding site on 
albumin molecule. In this regard, the Ka values in the 
absence and presence of varying drug concentrations were 
computed by using equations 42-46, a modified analysis of 
Levine's method (Levine, 1977). Scatchard plots of these 
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Fig. 42 . Kinetics of bilirubin displacement from its 
complex with albumin in the presence of about 20 
pM concentration of chlorpromazine (#•—•), 
indomethacin (O—O), and salicylic acid (O—O). 
The bilirubin over albumin ratio was 1.0 and 
albumin concentration was 5 jaM. 
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O 
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Fig.43(Aj, Indomethacin induced bilirubin displacement 
isotherms from its complex with albumin in the 
presence of 0 (•—•) , 20.1 yxVi (A—^), 50.0 yM 
(O—O) , and 100 ^M (•—•) drug concentration 
obtained in 50 mM sodium phosphate buffer, pH 
8.0, 1-0.15 at 28° C. The albumin concentration 
was ~ 5 pM. 
(B), Scatchard plots, obtained from the data of Fig. 
43 (A) by using equations 42-46.. 
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Fig.44(A). Salicylic acid induced bilirubin displacement 
isotherms from its complex with albumin in the 
presence of 0(•-•), 20.3 pM (A-A) , 50.7 pM (©—0) 
and 99.9 }iM (•-•) drug concentration obtained in 
50 mM sodium phosphate buffer, pH 8.0, I 0.15 at 
28° C. 
(B). Scatchard plots obtained from the data of Fig. 
44(A) bv usina eauations 42-46. 
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Fig.45(A) Chlorpromazine induced bilirubin displacement 
isotherms from its complex with albumin in the 
presence of 0(•—•), 20.1 pM (A-A) , 50.3 ;JM (<D-4&) 
and 100.7 pM (•-•), drug concentration obtained 
in 50 mM sodium pho^hate buffer, pH 8.0/ I 0.15 
at 28° C. 
(B) Scatchard 
Fig. 45(A) 
plots obtained from the 
by using equations 42-46. 
data of 
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displacement data are shown in Figs. 43-45 (B) and Ka values 
are summarized in Table XVIII. The values of association 
constant, computed by fluorescence enhancement (5.71xlO^M~^) 
was found to be somehow higher as compared to that obtained 
by fluorescence quenching (3.63x10^ M~^). It can be seen 
that at higher drug concentration ( 100 uM), the decrease 
in Ka is maximum with indomethacin followed by 
chlorpronazine and salicylic acid. These results obtained 
here, are in good agreement with earlier report (Brodersen 
et al., 1983). 
In order to explore the nature/mode of bilirubin 
displacement, the data were transformed into a typical 
double reciprocal plot by using the inverse values of 
fluorescence intensity at 528 nm and amount of bilirubin 
added. The displacement data at bilirubin/HSA molar ratio 
0-1.0 were taken into consideration, to specify the 
displacement nature of drug for displacing bilirubin from 
its primary binding site on albumin. The double reciprocal 
plots for these displacement studies are shown in Fig. 46 
A-C. The fitting of various points ware made according to 
the least squares method. 
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TABLE - XVIII 
ASSOCIATION CONSTANT* VALUES OF BILIRUBIN-HSA INTERACTION** AT VARYING 
CONCENTRATION OF DRUG 
DRUG CONCENTRATION 
Indomethacin 
Salicylic acid 
Chlorpromazine 
0 
20.1pM 
50.0 pM 
100.0 ;iM 
20.3 jiW 
50.7 pM 
99.9 pM 
20.1 pM 
50.3 pM 
100.7 pM 
ASSOCIATION CONSTANT, Ka 
(llt/oole) 
5.71X10^ 
1.47x10^ 
0.68x10^ 
0.51x10^ 
2.92x10^ 
1.66x10^ 
0.79x10^ 
1.11x10^ 
1.03x10^ 
0.66x10^ 
* In each case n < 1.0, 
** Obtained by fluorescence enhancement method. 
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Pig. 46 Double reciprocal plots for drug induced bilirubin 
displacement from albumin. Various drugs used for 
this study were : indomethacin (A), salicylic acid 
and chlorpromazine (C). The plots were 
transformed from the data of Figs. 43-45 (A) in 
Bil/HSA molar ratio 0.05-1.0. Various symbols 
used are the same as described in the legend to 
Fig. 43. 
DISCUSSION 
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Studies on the binding of serum albumin have been 
performed by a number of researchers using a diverse set of 
techniques like equilibrium dialysis, ultrafiltration, 
dynamic dialysis, circular dichroism, high performance 
liquid chromatography, microcalorimetery, gel filtration 
etc. This field of research is well reviewed by Kragh-Hansen 
(1981), Peters (1985), Lindup (1987), and Carter and Ho 
(1994). Majority of investigations on drug-albumin 
interaction were of qualitative nature and did not address 
to the problem of molecualr basis of this interaction. The 
study of drug albumin interaction is important firstly 
because the distribution of drugs to various tissues 
depends upon its binding to albumin and secondly many drugs 
cause displacement of bilirubin from its primary site on 
albumin. The drug induced bilirubin displacement has serious 
consequences in neonates. Understanding molecular basis of 
drug albumin interaction therefore, has great clinical 
significance. The present study is an attempt in this 
direction. 
Binding of ligands to protiens often produces decrease 
in protein fluorescence. This phenomenon of fluorescence 
quenching has been successfully used earlier to study the 
bilirubin - albumin interaction (Levine, 1977; Berde et al., 
1979; 1984; Tayyab and Qasim, 1989; Mir et al., 1992; 
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Minchiotti et al., 1993). 
In this study fluorescence quench tenchique has been 
established for interaction studies of various drugs to 
human serum albumin. All the three drugs which have been 
used in this study namely, indomethacin, salicylic acid and 
chlorpromazine produced quenching in albumin fluorescence 
when bound to this protein. The measurement of protein 
fluorescence as a function of concentration of these drugs 
therefore, served as a convenient and reliable method for 
measuring the association equilibrium constant under 
different sets of experimental conditions. 
The indomethacin - HSA interaction with an association 
constant (4.16x10^ M""^ ) obtained at pH 7.0, I 0.11 and 28*C 
by Scatchard plot according to the Levine's method (Levine, 
1977) compares well with association constant values(2.5x10 
to 1.5x10 M~ ) obtained earlier by equilibrium dialysis, 
ultrafiltration and circular dichroism (Mason and McQueen, 
1974, Ekman et al., 1980, Honre et al., 1983, Taira and 
Terada, 1985). From thermodynamic parameters, it can be seen 
that the negative free energy change for indomethacin-HSA 
interaction (^ -7.7 Kcal/mole) is due to the negative 
enthalpy change (-20.9 Kcal/mole). Since the value of 
entropy change are also negative (v^ -44 cal/mole. degree), 
this term would favour dissociation of indomethacin-HSA 
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complex. These thermodynamic parameters are similar to the 
AH'' (-13.6 Kcal/mole), As*^ (-8.5) cal/mole. degree) andAG° ( 
-11 Kcal/mole) values obtained earlier for bilirubin -
albumin interaction (Jacobsen, 1977) and suggest that like 
bilirubin-albumin interaction, indomethacin-HSA interaction 
also primarily involves hydrophillic interactions rather 
than hydrophobic interactions. A six fold decrease in Ka 
value of indomethacin-HSA interaction upon increase in ionic 
strength from 0.01 to 0.11 clearly suggests that 
electrostatic interactions play a crucial role in this 
interaction. As can be seen from Fig. 4 that only 
ionizable group of indomethacin i.e. carboxyl group ( pK 
4.5) would exist in anionic form at pH 7.0. Thus it seems 
obvious, that the carboxylate group participates in salt 
bridge formation with a positively charged group at its 
binding site in the protein, an identical situation to the 
binding of bilirubin to HSA (Brodersen, 1979).The pH 
dependency gave an apperant pk value of 4.6 which is close 
to the expected value of indomethacin. The pH can influence 
the binding in two possible ways, by changing the 
ionization behaviour of the protein and/or its conformation 
and by changing the ionization behaviour of drug. Besides 
the ionization of drug in pH range 3-6, the well known N..r^ F 
transition (Peters, 1985, Carter and Ho, 1994) would also 
effect the Ka values. Thus, these pH studies indicate that 
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either the ionization of drug or N^ r^ F transition of HSA or 
both contribute to the decrease in Ka at lower pH values. 
Since, other parameters storngly suggest involvement of 
electrostatic interactions it appears that the decrease in 
Ka with decrease in pH is primarily due to the protonation 
of drug with the N .«^  F transition of HSA playing only the 
secondary role. 
Generally, the results of drug-protein interactions 
obtained by binding eguilibrium studies are represented in 
terms of free and bound drug concentrations (Klotz, 1989). 
Experimentally such points (measurements) are straight 
forward. However, the analysis of these binding data is a 
much more complicated task. Determination of association 
constants usually results in higher variable figure (see 
Table III). It has been found that variation depend mainly 
upon cooperativity of ligand binding (Vorum et al., 1993). 
Furthermore, it is well known that cooperativity is 
generally absent on binding to HSA. The scatchard analysis 
has been used by several authors to analyse seriun albumin 
binding data (Kragh-Hansen, 1981; Klotz, 1982; 1989; Peters, 
1985). 
However the scatchard equation fails if cooperativity 
is present. The data, obtained here from fluorescence quench 
method were treated by scatchard equation according to the 
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Levine's method (Levine, 1977). There has been a significant 
discussion on traditional scatchard constants with number of 
independent sites with respect to Adair's constants 
(Fletcher et al., 1970; Klotz and Hunston, 1975; 1979; Weber 
and Andersen, 1965; Klotz, 1989). Therefore the modified 
version of iterative curve fitting procedure of Brodersen et 
al., (1987) by Vorum et al., (1993; 1994) was employed to 
check the earlier presented data based on traditional 
scatchard analysis. The role of cooperative binding was 
found to be negligible and values of primary association 
constant (Ka^), computed by new procedure (Vorum et al., 
1993) were found to be in close agreement with that 
obtaiend by commonly used Scatchard method (See Table 
VIII). A complete binding isothemn showed that one high 
affinity (contradictory to the results of EJcman et al., 
1980) and about six following (lower affinities) binding 
sites of indomethacin are present on albumin molecule. Being 
found to be in close agreement with best fit computer 
analysis, the scatchard analysis based on Levine's method 
was used to study the interaction of other ligands to HSA. 
The salicylic acid HSA interaction data gave the value 
of association constant (3.038x10^ M~^) at pH 7.0, I 0.11 
and 28 C which is in close agreement with earlier values 
(1.8x10^-2.2x10^ M~^) by equilibrium dialysis, 
ultrafiltration and frontal analysis chromatography (Mason 
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and McQueen, 1974; Brown and Crooks, 1976; Taira and 
Terada, 1985; Brodersen et al., 1987). The thermodynamic 
parameters for salicylic acid-HSA interaction with positive 
value of entropy (^  +2.0 cal/mole. degree) and relatively 
smaller value of enthalpy (— -7 Kcal/mole) resembles with 
the model studies of Kauzmann (1959) is an indication of 
involvement of hydrophobic interactions in this 
interaction. The presence of negative free energy change may 
oppose the hydrophobic nature of this interaction. A lower 
degree decrease in Ka (^ 2 fold) upon increase in ionic 
strength from 0.01 to 0.11, as compared to that obtained 
with indomethacin-HSA interaction studies states that 
electrostatic interactions may play a role in this 
interaction. The lone carboxyl group (pK'^S.O), existing in 
an anionic form at pH 7.0 seems to be available for salt 
bridge formation with positive charged group present in 
binding site. Earlier report has shown that Lys-199 of HSA 
undergoes acetylation with asprin, a derivative of salicylic 
acid (Walker, 1976). Thus, due to positive value of entropy 
(as an indication towards the involvement of hydrophobic 
interaction), it is quite obvious that electrostatic 
interactions play a secondary role in salicylic acid-HSA 
interaction. 
The effect of pH on Ka in the pH range 3-6 is of 
particular interest since in this region the lone carboxyl 
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gorup of drug would be titrated. Moreover, the N .<r^  F 
transition of HSA would also be enforced in this pH range. 
The changes in Ka, in this pH region resemble to a titration 
curve. The location of various derivatives of salicylic 
acid namely, 5-iodosalicylic acid, 3,5-diiodosalicylic 
acid, asprin has been shown in subdomains II A and IIIA of 
HSA by X-ray crystallography (He and Carter, 1992). Thus, it 
appears that ionization of carboxyl group of drug (mainly) 
or N-^F transition (Carter and Ho, 1994) of HSA or both are 
responsible for decrease in Ka at lower pH values. 
Chlorpromazine - HSA interaction with an association 
constant (1.684x10^ M~^) obtained here at 28'^ C, pH 7.0, I 
0.11 compares very well with the earlier reported values, 
4.2x10*- 1.9xlO^M"^ ( Gabay and Huang, 1974; and Sharpies, 
1975). Thermodynamic parameters for chlorpromazine-HSA 
interaction with a significant positive vlaue of entropy 
(+19.7 cal/mole. degree ) and least enthalpy change ( -1.27 
Kcal/mole) strongly suggests that hydrophobic interactions 
play a vital role in this interaction (Kauzmann, 1959; 
Testa et al., 1987; Brown et al., 1982; Urien et al., 1994). 
The net entropy increase ( S»0) mainly results from the 
disruption of ordered solvent cages around the hydrophobic 
surfaces of either the protein or the ligand on complexation 
(Smithrud and Diederich, 1990). 
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Expectedly, the increase in Ka with an increase in 
ionic strength supported the view that hydrophobic 
interactions are solely responsible for chlorpromazine-HSA 
interaction. The N -,r*- F transition (pH 3-6) has shown an 
insignificant change in Ka. This is an indication that 
binding site of chlorpromazine on HSA molecule is present 
either in domain I or II, since none of these domain under 
go any type of change during N „H^ F transition (Carter and 
Ho, 1994). Interestingly, N-^ r^ B transition (pH 7 to 10) has 
shown a prominant increase in Ka, which is consistant with 
earlier reports with warfarin - HSA interaction (Wilting et 
al, 1980a; 1980b). Additionally, N-c^B transition has been 
characterized for its unusual ligand binding property 
(Zurawaski and Foster, 1974; vander-Giesen and Wilting, 
1982; Dorge et al., 1982. Era et al., 1990; Carter and Ho 
1994). Moreover, ionization of tyrosine has been reported in 
basic pH range (Vorum et al., 1992). Therefore, two 
conclusion can be drawn from this study, first, that 
chlorpromazine binding site is located in domain I or in 
domain II, secondly, protonation of tyrosine residue in pH 
range 7-10 (at a faster rate ) may provide a mode of ion 
pairing with drug molecule. 
Modification of the constituent amino acid side chains 
of a protein has been used by different workers to 
investigate their role in maintenance of three dimensional 
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structure of protein, biological function, sequence analysis 
and ligand binding. The successful application of chemical 
modification of protein structure and function, among 
others, requires high degree of specificity of chemcial 
modification. The choice of amino group of HSA as 
modification site in this study was based on several 
considerations. The most important of these being their 
projected role in bilirubin binding and in the fact that a 
variety of slightly specific reagents are available for 
this side chain. 
Carbamylation of HSA attempted in this study is fairly 
specific for amino groups under the experimental conditions. 
(Stark, 1970; 1972; Nakagawa et al., 1972). Various 
carbamylated derivatives of HSA were obtained either by 
conventional modification, with modification of exposed 
lysine residues (Stark; 1972) and/or by double modification 
technique, having modification at buried residues (Mir et 
al., 1992). 
All of these modified preparations gave a single 
symmetrical peak on gel filtration and only one band on 
polyacrylamide gel electrophoresis. At pH 8.2, at which 
electrophoresis was performed the net negative charge on 
carbamylated would be in the order: 98% Cbl-HSA> 77% Cbl-
HSA> 55% Cbl- HSA >23% Cbl-HSA> (21%) Cbl-HSA, native HSA. 
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Hence, it is not surprising that 2 highly modified 
derivatives have lower electrophoretic mobility. It nay, 
however, also be pointed out that in addition to charge, 
electrophoretic mobility also depends upon hydrodynamic 
volume of protein. Increase in hydrodynamic volume lead to a 
decrease in electrophoretic mobility due to greater sieving 
effect. Therefore, it appears that these two highy modified 
preparations have undergone conformational changes. These 
results are in good agreement with earlier results, obtained 
on other modified preparations (Tayyab and Qasim, 1986). 
Moreover, (21%) Cbl-HSA shows a insignificant change in 
conformation, is almost identical to native and its own 
counterpart i.e. 23% Cbl-HSA with modification at exposed 
lysine residues. 
Gel filtration data, shows that 77% and 98% modified 
preparations of albumin undergo much pronounced 
conformational changes than other derivatives. This result 
is important since it shows that modification of buried 
lysine residues alone produce relatively small or no 
conformational changes and also proves the usefulness of 
double modification technique (Mir et al., 1992). 
The results on interaction of bilirubin with HSA were 
in good agreement with published results (Levine, 1977; 
Berde et al., 1979; 1984; Minchiotti et al., 1993). The 
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association constant vaule (3.63x10^ M"-*^' obtained here by 
fluorescence quench technique compares well with earlier 
reports (See table III). Earlier results from this 
laboratory (Tayyab and Qasim, 1987; 1989; Mir et al., 1992) 
on various modified derivatives indicated that buried lysine 
residues are critical for bilirubin - bovine serum albumin 
interaction. Similar results have been reported with other 
serum albumins (Islam et al., 1994; Tayyab et al., 1995). 
The modified derivatives in this study have confirmed that 
exposed lysine residues are not so important in bilirubin 
interaction with human serum albumin. Since (21%) modified 
HSA derivative has shown a 53 fold decrease in association 
constant, while in 23% modified HSA (a counterpart of 21% 
modified derivative) the decrease is insignificant. 
Interestingly a 76 fold decrease in Ka with maximally 
modified, 98% caramylated derivative is either due to the 
alterations in conformation (an increase in stokers radius 
from 3.4nm to 4.53 nm) with a result in disruption of 
binding affinity or to the accessibility of modifying 
reagent to the buried core residues of protein. However, a 6 
and 16 fold decrease ( with modification of 33 and 46 lysine 
residues of 60 present in protein) with 55% and 77% modified 
derivatives confirms our earlier prediction, that buried 
residues (s) are more crucial than exposed one in bilirubin-
HSA interaction. These results are in good agreement with 
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earlier reports (Tayyab and Qasim, 1987; 1989; Mir et al., 
1992; Tayyab et al., 1995) with bilirubin- albumin (bovine 
and sheep) interactions. 
As far as the identity of lysine residue(s) is 
concerned, Jacobsen (1978) first time identified Lys-240 of 
HSA for bilirubin interaction. Later the identity of lysine 
- 240 was questioned with following outcomes as Lys-220 in 
BSA (Jori et al., 1980; Petes, 1985) and Lys-195 in HSA 
(Reed and Mackay, 1985). More recently the position of Lys-
240 in HSA as a critical for bilirubin binding has been 
outlayed by Minchiotti et al. (1993). However, the possbible 
role of lysine residue (s) in this interaction can'nt be 
ruled out. Earlier thermodynamic data (Jacobsen, 1977) has 
revealed that salt bridge formation with carboxyl group of 
bilirubin and positive charge amino group takes place in 
bilirubin-albumin interaction (Brodersen, 1979). The value 
of AG** for the contribution of salt bridge to free energy as 
2.8 Kcal/mole (Mir et al., 1992) has been found in good 
agreement for salt bridge fromation (Saali et al., 1991) and 
Lightner et al. (1988a) has made the confirmation of 
involvement of one salt bridge in this interaction. It is 
believed that bilirubin binding site on HSA is located 
somewhere in IIA subdomain (Carter and Ho, 1994). 
Therefore, it appears that one or two lysine residues, 
(present in the hydrophobic cavity of IIA) interact with 
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carboxyl group of bilirubin to form a salt bridge. 
Moreover,it appears that either Lys - 225 (HSA) or Lys 
225/222 (BSA) serves as binding site in IIA (buried in) of 
albumin. 
The mechanism of interaction between bilirubin and 
albumin is not known in its full details. Kinetic studies 
show that this interaction is biphasic (Jacobsen and 
Brodersen, 1983) involving a fast step and a slow step in 
which relaxational changes in albumin molecule takes place. 
The second phase is believed to involve the rotation of one 
half domain of albumin binding with one dipyrrole ring of 
bilirubin relative to other half domain binding second 
dipyrrole ring of bilirubin (Jacobsen and Brodersen, 1983). 
On the other hand it has been proposed that bilirubin 
exists in an equimolar mixture of two enantiomeric forms 
one of which prefrentially binds with albumin (Lightner 
et al., 1986; 1988b). Therefore, it seems probable that 
during second step (conformational relaxational)the buried 
lysine residue become accessible for interaction with 
bilirubin. 
The indomethacin interaction with modified derivatives 
have shown a clear trend towards the participation of buried 
lysine residues in this interaction. A 52 fold decrease in 
association constant with (21%) Cbl-HSA clearly indicate 
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the sole participation of buried lysine residues in salt 
bridge formation with carboxyl group of drug since only a 9% 
decrease in Ka with maximally modified derivative i.e. 98% 
modified was obtained, it seems to be due to conformational 
alteration upon modification. A marginal decrease (2 to 7 
fold) in Ka with other preparations confirms that the 
buried lysine residues are critical in this 
interaction. Earlier report has shown that indomethacin 
utilises both, diazepam and bilirubin (Honore et al., 1983), 
while another study, (Maruyama et al.,l985) has also 
indicated that bilirubin binding site is nearby to 
diazepam sit (Sudlow class I) while away from digitoxin 
site ( Sudlow class II). It appears plausible that being 
similar in binding nature the binding site of bilirubin and 
indomethacin are different, since a 9 fold decrease was 
obtained with indomethacin and 76 fold with bilirubin to a 
maximally modified (98%) derivative of HSA. At this moment 
it appears that if the bilirubin binding site is located 
in IIA, ( according to Carter and Ho, 1993) the 
indomethacin site may be located in IIA, IIIA subdomains. 
Interaction of salicylic acid with modified derivatives 
of HSA have shown an opposite trend with that obtained 
with bilirubin and indomethacin interaction studies. No 
signficant decrease in Ka upto a mark of 55% modification 
and a 51 fold decrease in Ka with 98% modified derivative 
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indicate that the exposed lysine(s) play an important role 
in binding. Earlier, the location of various derivatives of 
salicylic acid as in IIA, IIIA subdomain has been discussed 
in the light of X-ray crystallographic study (He and Carter, 
1992). Walker (1976) showed Lys-199 of HSA as site for 
aspirin, a derivative of salicylic acid. Interestingly 3 
fold decrease in Ka with (21%) modified derivative, having 
modification at buried lysine residue. Therefore, it seems 
that the binding site on HSA is located in IIA, IIIA 
subdomain and is exposed (partially/fully) in nature. This 
study is found to be in good agreement with earlier result 
stating that salicylic acid binding site is exposed to 
solvent (Gerig et al., 1981). 
Interaction of chlorpromazine with modified derivatives 
of HSA on the other hand was not affected by acylation of 
lysine residues. As can be seen from Table XVII there is an 
insignificant decrease in Ka upon chemical modification. 
Thus it seems that lysine residue does'nt participate in 
chlorpromazine - HSA interaction. A minor decrease may be 
accounted for conformational changes. The earlier studies 
(Carter and Ho, 1994) and various other data, based on 
temperature, ionic strength and pH as discussed earlier, 
states that possibly this cationic drug, chlorpromazine 
binds somewhere in domain I or near to subdomain IIA. 
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The value of association constant for bilirubin - HSA 
interaction (5.71x3 0 M~^ ) , obtained by fluorescence 
enhancement technique was in close agreement with the 
earlier reported values (see Table III). The close agreement 
in Ka value by fluorescence enhancement technique with those 
obtained by other techniques show usefulness of this 
technique in studying bilirubin - albumin interaction. It 
can be seen that Ka for bilirubin-albumin interaction, 
obtained here gave a fair value as compared to that 
obtained by fluorescence quench method (i.e. 3.63x10 M"-*-). 
It can be seen that at higher concentration of drug, namely 
100 uH the displacement in case of indomethacin was found 
to be maximum ( ^ ^ 11 fold) followed by with chlorpromazine 
and salicylic acid with a mark of decrease in Ka as 9 and 7 
fold respectively. This outcome fits well with earlier 
report (Brodersen et al.,1983; Brodersen and 
Ebbessen,1983). In case of indomethacin, a concentration in 
4.2 to 12.6 uM have not signified any change in 
displacement (Lam and Wong, 1990). The results summerised 
here fits well with earlier reports, ie and Levy, 1979a; 
1979b; Brodersen et al., 1983; Brodersen and Ebbessen, 
1983). Additionally, this technique has shwon an advantage 
since peroxidase technique,used for displacement task showed 
some false out comes (Brodersen et al.,1979). 
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As can be seen that the double reciprocal plots (Fig. 
46) with an increase in slope with increase in drug 
concentration, without affecting the intercept (in case of 
indomethacin) resembles to a plot with competitive in 
nature. Thus, it appears that the indomethacin induced 
bilirubin displacement is of competetive type. Moreover, 
increase in both slope and intercept with an increase in 
salicylic acid concentration shows that the salicylic acid 
displaces bilirubin non competetively. This outcome is in 
good agreement that both (drug and bilirubin) have different 
binding sites. Thus, possibly after interacting on its 
site, salicylic acid - HSA complex causes a conformational 
changes, leading to the release of bilirubin from albumin. 
In case of chlorpromazine the situation seems more complex, 
as both the values of intercept and slope changes. So 
probably chlorpromazine displaces bilirubin both 
competetively as well as non competetively. 
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